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ABSTRACT
Herpetic stromal keratitis (HSK) is an immunopathological and tissue
destructive corneal lesion caused by herpes simplex virus (HSV) infection, which
induces an intense inflammatory response and finally leads to blindness.
Accumulating evidence using the murine model has shown that Th-1 phenotype
CD4+

T

cells

orchestrating

the

inflammation

mainly

contribute

to

the

immunopathological reaction in HSV-1 infected cornea. Initially various innate
immune cells recruit and produce numerous inflammatory and angiogenic
molecules

into

the

corneal

stroma

those

in

turn

drive

the

corneal

immunopathology.
While the basic principles of immunity to the influenza A viruses (IAV) are
probably similar for all vertebrates, detailed understanding is based largely on
experiments in laboratory mice. Virus clearance is normally mediated via CD8+
effector T cells but, in their absence, the class-switched antibody response can
ultimately achieve the same goal. Influenza virus-specific plasma cells and CD8+
T cells persist in the long term and the recall of the CD8+ T cell response can lead
to earlier virus clearance.
The first part (Part I) of this dissertation focuses on the understanding of
HSV-1 induced immunoinflammatory processes in the cornea and the secondary
lymphoid tissues and the involvement of immuno-modulatory mechanisms
following acute viral infections such as HSV and IAV. The next three parts (Part IIIV) focus on different inflammatory and counter-inflammatory mechanisms that
iii

are activated following acute viral infections. Results in Part II evaluate the role of
small molecule inhibitors of VEGFR2/src kinase inhibitors in controlling the
progression of the inflammatory lesions after ocular HSV infection. Results of the
third section show that the host counter inflammatory mechanisms inhibit tissue
damage but these may also act to constrain the effectiveness of immunity to acute
infections. The fourth section describes the functional significance of HVEM
expression on regulatory T cell in their expansion following HSV-1 infection.
In this study, experiments were designed to understand the mechanisms
involved in the regulation of immunity and resultant immunopathology using HSV1 and IAV as the model systems and that modulation of these processes can
enhance immune response and diminish immunopathology following acute
infections.

iv

TABLE OF CONTENTS
Part
I

Page

Background and Overview.................................................................1
Animal models and pathogenesis of SK.................................................3
Immunity and Immunopathology to IAV................................................12
Conclusion.............................................................................................19
List of references...................................................................................20
Appendix...............................................................................................29

II

An anti-inflammatory role of VEGFR2/src kinase inhibitor in HSV-1
induced immunopathology................................................................34
Abstract................................................................................................35
Introduction..........................................................................................36
Materials and Methods.........................................................................38
Results......................................................................…………………..45
Discussion............................................................................................53
List of references..................................................................................59
Appendix..............................................................................................63

III Tim-3/Galectin-9 interaction regulates influenza A virus specific
humoral and CD8 T cell responses...............................................79
v

Abstract.............................................................................................80
Introduction........................................................................................81
Materials and Methods......................................................................82
Results..............................................................................................88
Discussion........................................................................................95
List of references............................................................................100
Appendix.........................................................................................104

IV Regulatory T cell expression of Herpes virus entry mediator (HVEM)
following HSV-1 infection and its functional significance.........128
Abstract...........................................................................................129
Introduction......................................................................................130
Materials and Methods....................................................................132
Results............................................................................................136
Discussion.......................................................................................142
List of references.............................................................................148
Appendix.........................................................................................151

V Conclusion.....................................................................................169

VITA................................................................................................171

vi

LIST OF FIGURES
Part
I

Figure

Page

Figure 1. Principal cellular events in herpetic SK pathogenesis...................30
Figure 2. Herpes virus entry mediator and its ligands………………………..31
Figure 3. Schematic representation of consequences of Tim-/Galectin-9
Interaction ………………………………………………………………………...32

II

Figure 2.1. Effect of topical administration of src kinase inhibitor (TG100801)
on the severity of SK......................................................................................65
Figure 2.2. TG100801 inhibits FAK-y861 phosphorylation in the murine
cornea...........................................................................................................66
Figure 2.3. TG100572 controls SK lesion severity independent of viral
replication......................................................................................................67
Figure 2.4. Effect of systemic administration of src kinase inhibitor
(TG100572) on angiogenesis and SK lesion severity...................................69
Figure 2.5. Representative eye photograph (at day 15 p.i.) of control (a) and
TG100572 treated (b) mice...........................................................................70
Figure 2.6. Kinetics of Cellular infiltration in the corneas of control and
TG100572 treated mice.................................................................................72
Figure 2.7. TG100572 treatment diminishes the infiltration of pathogenic Th1

vii

cells in the cornea…………………………………………………………………74
Figure 2.8. TG100572 treatment results in the blockade of CXCL1 in the
cornea…………………………………………………………………………….76
Figure 2.9. Src kinase inhibition may result in the attenuation of T cell
function……………………………………………………………………………78

III Figure 3.1. Tim-3 expression is up regulated on virus-specific CD8 T cells
after IAV infection.......................................................................................106
Figure 3.2. Galectin 9 induces apoptosis of IAV NP tetramer specific and Tim-3+
CD8 T cells in vitro…………………………………………………………..108
Figure 3.3. Gal-9 knockout animals mount stronger virus-specific CD8 T cell
responses in the acute phase.....................................................................110
Figure 3.4. Enhanced virus-specific antibody production in G9KO mice after
influenza infection.......................................................................................112
Figure 3.5. Gal-9 knockout mice develop more robust recall responses to
influenza A virus upon heterologous challenge..........................................114
Figure 3.6. Administration of Tim-3 fusion protein in mice after IAV infection
enhances the magnitude and quality of IAV-specific CD8 T cells
responses..................................................................................................116
Figure 3.7. Outcome of infection with IAV HKx31......................................118
Figure 3.8. Cells obtained from broncho-alveolar lavage (BAL) were stained for
CD45+ and CD45+CD11b+Ly6G+ ...............................................................120

viii

Figure 3.9. Lung Histopathology................................................................122
Figure 3.10. Characterization of CD4+FoxP3+ regulatory T cells from WT and
the G9KO mice………………………………………………………………….124
Figure 3.11. Adoptive transfer of memory CD8 T cells……………………..127

IV

Figure 4.1. HSV-1 infection results in the expansion of CD4+FoxP3+ regulatory
T cells.........................................................................................................153
Figure 4.2. HVEM expression is up regulated on regulatory T Cells following
HSV-1 infection and its viral ligand is expressed in PLN following
infection………………………………………………………………………….155
Figure 4.3. Primed cells stimulated with HSV causes HVEM up regulation on
Tregs..........................................................................................................157
Figure 4.4. Recombinant HSV-1 gD increases the proportions of FoxP3+ T cells
among CD4+T cells....................................................................................159
Figure 4.5. HSV-1gD can help to expand Tregs........................................161
Figure 4.6. Diminished representations of CD4+FoxP3+ regulatory T cells in the
HVEM knockout mice.................................................................................163
Figure 4.7. Reduced numbers of CD4+FoxP3+ per CD4+FoxP3-T cells in HVEM
knockout mice............................................................................................165
Figure 4.8. Diminished frequencies of activated Tregs in HKO animals ...167
Figure 4.9 Influence of HVEM expressing T regs on outcome of immune
response to HSV........................................................................................168

ix

ABBREVIATIONS
APC...........................……..Antigen presenting cell
BTLA………………………..B and T lymphocyte attenuator
CCL2, 5, 20........................Chemokine (C-C motif) ligand 2, 5, 20
CD..................................... Cluster of differentiation
CTL....................................Cytotoxic T lymphocyte
COX-2................................Cyclooxygenase-2
CXCR2..............................CXC chemokines receptor 2
CXCL3, 8...........................CXC chemokine ligand 3, 8
DC…………………………..Dendritic cell
FGF....................................Fibroblast growth factor
Gal-9………………............Galectin-9
G9KO………………………Galectin-9 knockout
HKO………………………..HVEM knockout
HVEM……………………...Herpes virus entry mediator
HSV-1................................Herpes simplex virus 1
HSV-1gD…………………..Herpes simplex virus 1 glycoprotein D
HSK...................................Herpetic Stromal Keratitis
IAV……………………….…Influenza A virus
ICAM-1..............................Intercellular adhesion molecule 1
IFN-α, γ.............................Interferon alpha, gamma
IL-1, 2, 6, 12, 17, 18, 23... IL-18 Interleukin 1, 2, 6, 12, 17, 18, 23
x

BP.....................................Binding protein
IP-10.................................Interferon inducible protein 10
KC.....................................Keratinocyte-derived chemokine
LT…………………………..Lymphotoxin
LTa…………………………Lymphotoxin alpha
LTbR……………………….Lymphotoxin beta-receptor
MCP-1.............................. Monocyte chemoattractant protein 1
MIP-1, 2......................…...Macrophage inflammatory protein 1,2
MMP-9..............................Matrix metalloproteinase-9
NFκB.................................Nuclear factor- kappa B
PECAM.............................Platelet endothelial cell adhesion molecule
PFU..................................Plaque forming unit
PGE2...............................Prostaglandin E2
PMN.................................Polymorphonuclear leukocyte
PAMP...............................Pathogen Associated Molecular Patterns
siRNA..............................Small interfering RNA
SK....................................Stromal Keratitis
SCID………………………Severe combined immunodeficiency
TGF-β...............................Transforming growth factor beta
TIMP.................................Tissue inhibitors of metalloproteinases
TLR 2, 4, 9........................Toll like receptor 2, 4, 9
TNF-α................................Tumor necrosis factor alpha
VEGF..............................Vascular endothelial growth factor
xi

VEGFR2…………………Vascular endothelial growth factor receptor 2
VLA4...............................Very late antigen 4
Treg................................Regulatory T cell
Tim-3……………………..T cell immunoglobulin and mucin protein

xii

PART I
BACKGROUND AND OVERVIEW
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IMMUNOPATHOLOGY AND IMMUNITY TO HSV-1
Clinical Background
Herpes simplex virus (HSV) induced eye diseases are one of the
commonest causes of unilateral infectious blindness in the western world.
Epidemiological studies in the United States reveal that, 400,000 persons are
affected, with 20,000 new cases occurring annually with the incidence ranging
from 4.1- 20.7 cases/100 000 patients per year (9, 87). Results from surveys
conducted by the National Health and Nutrition Examination between 1976 and
1980 (NHANES II) and again between 1988 and 1994 (NHANES III) showed a
30% increase in HSV-2 specific antibodies within the studied timeframe in the
United States (67) . In contrast the age specific seroprevalence of HSV-1 has
decreased in industrial countries with the exception of several developing
countries (67) . Ocular lesions are mostly caused by HSV type 1 and very rarely
by HSV type 2 infections. However, 80% of neonatal herpes infection is caused
by HSV-2, although both strains can be involved.
Classically, the life cycle of HSV in the host is divided into four stages
namely, entry, spread, establishment of latency and reactivation. After the
primary infection of the skin or mucosal surfaces with HSV, it spreads to the
neuronal cell bodies where latency is established. It is currently believed that the
virus reactivation is kept in check by host immune cells in the sensory ganglion
(82). The psychological and physical stresses that result in temporary impairment
of the immune system facilitate the reactivation of HSV and subsequent release
of the virus to the periphery (26). Most ocular HSV infections result in acute
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epithelial keratitis that can be controlled with several antiviral drugs (42) . Twenty
% of the patients infected ocularly with HSV develop, a chronic vision impairing
stromal lesion known as herpetic stromal keratitis (HSK). In humans,
approximately 50% of HSK occurs as a consequence of virus reactivation from
the trigeminal ganglion and only ~2% of such cases result directly from primary
HSV infection. The chances of developing SK are three times greater following a
recurring herpetic keratitis than following a primary infection.
Symptoms of HSK lesions include corneal necrosis and ulceration along
with stromal edema and neovascularization (16) . These lesions are shown to
occur mainly as a result of T cell mediated immunopathological responses in the
cornea whose pathogenesis is poorly understood. Forty to ninety percent of the
patients with stromal keratitis may develop disciform keratitis (corneal
endothelium is the main site of damage), while the rest of the patients may
develop stromal opacities. If not treated properly, it may lead to corneal scarring
and ulcerations warranting corneal transplantation. Apart from stromal keratitis,
HSV infection can also result in viral retinitis and/or encephalitis in
immunosuppressed and immunocompetent individuals. In some cases, infection
with HSV-1 or 2 have also been reported to be associated with acute retinal
necrosis syndrome.
Animal models and pathogenesis of SK
Most of the studies to elucidate the pathogenesis of HSK have been
performed in animal models for human HSK. For primary infection, the mouse is
the most studied animal species, while the rabbit is the preferred animal for
3

recurring infection. However similar types of lesions occur after primary or the
recurrent infection (83). Understanding progressing events that finally lead to
corneal inflammation has mainly come from primary ocular infection in mice.
Several

strains

of

mice

including

both

immunocompromised

and

immunocompetent animals such as BALB/c, C57BL6, CAL-20, 129/SVEV have
been described for studying HSK (16) . In immunocompetent animals SK lesions
are evident within 6-7 days after ocular infection with HSV-1 that peak in severity
between 15-21 days. The lesions are primarily caused by CD4+ T cells that are
detected in abundance at day 7-8 pi and most of which are likely to be HSV
reactive. Another model uses TCR transgenic mice on a RAG–/– background,
which have been shown to develop SK upon ocular infection with HSV, even
though their CD4+ T cells were almost all reactive with OVA323-339 peptide and
not detectably cross-reactive with HSV antigens (28). The CD4+ T cells in the
ocular lesions of such animals were shown to react with the KJ1.26 mAb noted
by others to react with the TCR of H-2d CD4+ T cells that recognize the OVA323339 peptide (35) . Since this KJ+ TCR had no demonstrable reactivity with HSV, it
was thought that the activation of KJ+ CD4+ T cells was not TCR mediated but
involved activation by one or more cytokines (30) . This model was referred to as
a bystander model of SK (29) . Yet another model that has been characterized is
SK induced in SCID mice after reconstitution with CD4+ but not CD8+ T cells
isolated from either HSV immune or naïve animals (80, 87, 93). All these animal
models present typical SK lesions characterized by corneal haze, edema,
necrosis, ulceration and neovascularization.
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Ocular infection with HSV 1 in immunocompetent animals is followed by
initial replication of virus especially in the corneal epithelium for up to 5-6 days.
Live viral particles and the transcribed mRNA copies of viral genes can be
detected from the corneal swabs during this time but not beyond 7 days post
infection using conventional viral titration and RT-PCR assays respectively (9).
However, viral DNA could be detected in the cornea even up to 21 days post
infection (pi), the time when the disease is at its peak and spontaneous healing
may start in a minority of animals. The nature and pathophysiological significance
of the persisting viral genomic DNA in terms of its transcriptional and translational
efficiency to make viral proteins is not yet elucidated. Studies focused on these
aspects would shed light on some of the previously unknown players in the
causation of SK.
After the initial phase of viral infection and replication in the cornea, there
is a prominent infiltration of inflammatory cells near the corneal epithelium that
mainly consists of neutrophils (PMN) (92). These cells could potentially exert
anti-viral defense by producing nitric oxides, reactive oxygen species, TNF-α,
IFN-γ or perhaps just by engulfing viral particles. Furthermore, the kinetics of
their infiltration correlates with the clearance of replicating virus from the cornea
as shown in Fig.1 (All figures are supplied in an appendix). Other studies where
neutrophils were depleted prior to ocular HSV infection showed a delay in viral
clearance from the cornea (96). In addition to their role in viral clearance, they
may also provide conducive conditions for the ensuing inflammatory response by
releasing mediators such as IL-1β, IL-8 (MIP-1α) IL-12 and TNF- α. Neutrophil
5

secreted NO could unmask corneal antigens that can be a continuous source for
the influx of reactive T cells. The matrix metalloproteinases such as MMP-9 can
cause break in stromal matrix and along with neutrophil or perhaps stromal cell
secreted VEGF-A contribute to the neovascularisation of usually avascular
cornea. Recently it has been shown that VEGF-A is indeed present in the cornea
and being bound to a soluble form of the VEGF receptor-1 impedes its
angiogenic activity. Ocular neovascularization resulting from HSV infection
involves a change in the balance between VEGF-A and its soluble inhibitory
receptor (85). Inhibition of angiogenesis by targeting MMP-9 and VEGF by siRNA
approach were shown to reduce the extent of neovascularization (4, 44). Some
additional angiokines such as bFGF, E-L-R motif containing chemokines (MIP-2)
are also up regulated in cornea after HSV infection (107). In addition to PMNs,
other cells such as DCs, NK cells, γδ-T cells, macrophages etc. could contribute
both towards viral clearance and the subsequent inflammation by secreting type I
IFNs, and other cytokines as well as chemokines such as IL-6, IL-1β, IL-12, MIP2, TNF-α, IFN-γ, IL-23, IL-17 (9). Once the vascular bed is formed, there is
continuous infiltration of cells because of leakage of newly formed vessels. IL-1
and IL-6 were shown to be the critical cytokines to initiate the subsequent
inflammatory events and could be produced by epithelial cells initially after viral
infection. HSV DNA and perhaps some of its other components expressing
PAMPs can activate PRR such as toll like receptors (TLRs)-2,4 and 9 on the
innate cells which provide stimulation for the activation of the NFκB pathway (76).
CpG motifs derived from viral DNA in the cornea could stimulate TLR 9 and
6

induce IL-1 and IL-6 which contribute to the immunopathological lesions along
with an efficient induction of adaptive immune response (110). IL-6 could be
produced by un-infected cells by IL-1 stimulation in a paracrine manner which in
turn trigger MIP-2 (also known as CXCL8) production that is involved in the
attraction of PMNs. COX-2, is another important mediator of inflammation that
could be induced by IL-1 in the cornea and acts through production of PGE2 (23)
. Recent studies have shown the important role of TNF-α in the causation of SK.
Animals lacking this cytokine were unable to control the virus in cornea and thus
exhibited enhanced lesion severity (55) .
IL-12 produced by PMNs, macrophages and Langerhans DCs was shown
to be another important candidate cytokine involved in the pathogenesis of SK
(48, 63) . It is involved in the downstream production of IFN-γ by macrophages,
NK cells, neutrophils and CD4+ T cells. Both proinflammatory and antiinflammatory activities have been attributed to IFN-γ. It aids in the PMN influx by
up regulating PECAM-1 and ICAM-1 on corneal epithelial cells (90, 108),
endothelium cells and keratocytes needed for the exit of inflammatory cells. It
also helps to prime the CD4+ T cell responses by up regulating MHC II on
antigen presenting cells. The most important anti-inflammatory activity of IFN-γ is
attributed to its potential of inducing anti- angiogenesis factors including, but
probably not limited to, IP-10 (51). Its role in promoting Foxp3+ regulatory T cells
induction was also described recently (21, 22, 99). IL-23/IL-17 axis is another
identified pathway involved in pathogenesis of various types of autoimmune
inflammatory lesions. IL-23 produced by innate cells such as DCs is responsible
7

for the stabilization of cells with the Th17 phenotype. IL-17 produced by
inflammatory Th17 or perhaps fibroblast or neutrophils help recruit more PMNs.
The role of IFN-γ producing Th1 cells is well studied in SK pathogenesis but a
precise role of Th17 cells has not yet been described. In mouse SK lesion CD4+
T cell outnumbers CD8+ T cells but the reasons for their preferential
accumulation remains unclear (61) . The inflammatory reaction in the trigeminal
ganglion has a preponderance of CD8+ T cells in addition to CD4+ T cells. The
antigen-specificity of CD4+ T cells that infiltrate cornea remains largely unknown
because of a lack of specific CD4+ T cells epitope derived from HSV or the
tetramer. It is anticipated that CD4+ T cells that infiltrate into cornea initially
constitute a population enriched in HSV reactivity. Later on lesions would be
dominated by bystander cell populations. Because of less stringent requirements
of antigenic stimulation of Th17 cells (101), it is possible that the role of these
cells in the pathogenesis of SK predominates in the later stages of inflammation
where viral antigen availability is limited. Thus, one valid hypothesis could be that
the acute phase is mainly dominated by Th1 cells while the chronicity of lesion is
maintained by Th17 cells. Some of our initial published observations support this
hypothesis (86).
Current treatment modalities
Presently the therapeutic agents used for treating acute keratitis include
the administration of antivirals and corticosteroids and non-steroidal antiinflammatory drugs such as Cyclooxygenase-2 (COX-2) blockers (7, 16, 105).
Prolonged use of antivirals was shown to result in the development of resistance
8

particularly in immunocompromised individuals (10, 13). Similarly use of
corticosteroids might give rise to numerous adverse effects (14, 45) and in some
patients it may exacerbate HSK lesions due to enhanced HSV-1 replication
(102). Animal studies in the mouse model of HSK have demonstrated that
cytokine and chemokine blockers such as the IL-1 receptor antagonist are
effective (8) . As neovascularization is an essential event for HSK pathogenesis,
siRNA against VEGF was shown to be effective in reducing HSK lesions in the
mouse (44) . Recent studies have shown that VEGF-induced vascular leakage is
mediated by cytoplasmic protein kinase members of the Src proto-oncogene
family in brain, heart, and other tissues (20, 109) (65, 103). Such vascular
permeability is likely related to a loss of integrity in adherens junctions, which
regulate cell-cell adhesion. VEGF has been shown to activate the Src family of
tyrosine kinases (SFKs), leading to tyrosine phosphorylation of adhesion junction
components, including VE-cadherin and its associated proteins β-catenin and γcatenin, which are important to endothelial cell adhesion(20, 43, 64, 103, 104) .
Abnormal vascular permeability is frequently associated with neovascularization
(77). Endothelial cell barrier functions are disrupted by a number of viruses and a
recent study suggests that VEGFR2 and SFK inhibitors may be of therapeutic
utility in stabilizing vasculature during viral infections (33) . Furthermore, mouse
model studies also support the effectiveness of regulatory T cell therapy in
controlling HSK immunopathology (80) .
Regulatory T cells as an immunotherapeutic
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The magnitude of a T cell mediated immune response to an acute viral
infection may be influenced by the activity of one or more types of regulatory T
cells (Tregs) (87, 88), particularly those that express FoxP3. For example HSV-1
infection results in the activation and expansion of regulatory T cells and the
majority of expanded Tregs are not antigen specific. It is conceivable that the
Treg expansion following an acute viral infection could be an immune evasion
strategy employed by the virus to dampen the antiviral CD8 T cell responses (5)
or conversely it could be a counter inflammatory mechanism imposed by the viral
infected host itself to prevent the immune mediated collateral tissue damage
(72). In addition to other mechanisms such as the cytokine IL-10 (71, 87) Treg
are shown to be involved in controlling the ongoing inflammatory processes in
the cornea (87) . In addition, these cells might help in the resolution of the clinical
lesions and in model systems in which the activity of Treg cells can be inhibited,
tissue-damaging immunopathological reactions to some viruses are increased
(87). How HSV infection triggers Treg expansion and the molecular interactions
responsible for their suppressive activity remains poorly understood. Additionally,
since the expanded Treg population is largely non-specific to HSV, TCR (T cell
receptor) mediated events likely play at most a minor role.
HSV entry into cells requires binding of the envelope glycoprotein D (gD)
to HVEM (a TNF receptor family member) receptors on the cell (46). Besides
being an entry receptor for HSV, HVEM is identified as a co-stimulatory molecule
that is known to be constitutively expressed on the cells of immune compartment.
HVEM can promote T cell activation by propagating signals from the TNF super
10

family member ligand, LIGHT, a lymphotoxin related inducible ligand (100) that
competes with glycoprotein D for binding to HVEM on T cells or can deliver
inhibitory signals upon binding with BTLA (B and T lymphocyte attenuator) (Fig
2). In a previous report HVEM knockout mice were shown to develop an
unexpected enhancement of T cell responses (98), with increased susceptibility
to autoimmunity and that over expression of HVEM enhances Treg suppressive
function (91) suggesting a role of HVEM in Treg suppressive function.
Importantly T cells from scurfy mice have been shown to lack HVEM expression
even after activation (91), suggesting an involvement of FoxP3 in regulation of
HVEM expression.
BTLA and CD160 binding to HVEM has an important role in antagonizing
and down regulating effector cell function activated directly or indirectly by LIGHT
and LT binding to HVEM or LTbR. The inhibitory functions of BTLA and CD160
may be distinct and non-redundant as suggested by their distinct expression. In
addition, the TNF family ligands of HVEM (LIGHT and LTa) bind to LTbR and are
important for immunoregulation by shaping the lymph node architecture and DC
expansion and homeostasis. Therefore, HVEM may serve as a ‘negotiator’
balancing co-inhibition by BTLA ⁄ CD160 and co-stimulation by LIGHT ⁄ LTa ⁄
LTbR in order to achieve an immunobalance. But overall, the role of the newest
ligand in the HVEM pathway, CD160, in these diseases remains to be
determined and studies with mice deficient in CD160 and doubly deficient in
CD160 ⁄ BTLA are needed to answer these questions (11). Taken together,
although HVEM binding to LIGHT and LTa delivers a positive signal to T-cell
11

activation, the overall function of HVEM is inhibitory, suggesting the negative
signals mediated by BTLA and CD160 are dominant. Therapies targeting the
CRD1 of HVEM to block BTLA and CD160 binding are being developed to
enhance immune responses and vaccination (50) and increasing BTLA
expression levels in the cornea to prevent HSV-1 induced immunopathology
(106).

IMMUNITY AND IMMUNOPATHOLOGY TO IAV
Respiratory virus infections are a major cause of morbidity and mortality
throughout the world. A major challenge for immunologists is deciphering the
underlying mechanisms of immune protection at mucosal surfaces such as the
lung epithelium. Understanding the individual steps of an immune response in
the lungs is essential if we are to develop vaccines that elicit effective immunity in
the lung.
Influenza virus infections alone result in the deaths of about 36,000 people
per year in the United States and there is tremendous concern that highly lethal
variants of this virus may emerge and cause a major pandemic (39, 60).
Moreover, the emergence of new respiratory pathogens, such as the corona
virus associated with Severe Acute Respiratory Syndrome, poses a continual
threat (66). Despite the medical significance of respiratory viral infections,
satisfactory vaccines have not been developed. For example, in the case of
influenza virus, the currently available vaccine elicits humoral immunity specific
for viral coat proteins and must be reformulated yearly to be effective against
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new viral strains (31). Recent progress in our understanding of cellular immune
responses in the lung will facilitate the development of effective vaccines.
Immunity in the respiratory tract
Much of our understanding of immune responses to respiratory virus
infections has been derived through experimental animal models. A particularly
robust and well-characterized model is the infection of mice with mouse-adapted
influenza virus(6, 18, 69). When introduced through the nose, the virus
establishes infection of lung epithelial cells and elicits powerful cellular and
humoral immune responses in the lung. CD8+ cytotoxic T cells first appear in the
lung airways on day 7 post-infection and play a key role in clearing virus(24) .
Typically, this effector T-cell response peaks around day 10 or 11 (24). Antibody
is also generated in the response, but isotype switched antibody does not
accumulate until day 7 and does not appear to play a critical role in the primary
infection unless the viral titer is particularly high (34) . Following resolution of the
infection, memory T cells persist in secondary lymphoid organs, such as the
spleen and local draining lymph nodes, as well as a variety of peripheral sites,
including the lung parenchyma and airways (38, 53). These memory cells retain
the capacity to mediate accelerated recall responses due to their semi-activated
status and increased precursor frequencies relative to naive T-cell populations
(12, 24, 37, 38).
While the basic outline of T-cell immunity in the lung has been
established, the specific details remain obscure. The advent of new technologies
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for studying immune responses in vivo has allowed viral immunologists to begin
to visualize key processes and dissect the underlying mechanisms.
Primary T-cell responses
The infection of respiratory epithelial cells initiates a cascade of events
that culminate in the activation of a cellular immune response in the lung. The
initial infection induces the production of inflammatory mediators by epithelial
cells, which alert the innate immune response to the infection (17) . In addition,
dendritic cells (DCs) lining the upper respiratory tract also detect the presence of
an infection via toll-like receptors (TLRs), which detect viral proteins (49) or
products of viral replication, such as double stranded RNA (2, 17, 36, 49, 95) .
The combination of inflammation and TLR signaling activates DCs, increases
their expression of class I and class II Major Histocompatibility Complex (MHC)
molecules and induces a wide array of co-stimulatory and adhesion molecules as
well as inflammatory cytokines that are required for the induction of T-cell
responses (54, 56). Together, these changes in DC activity result in enhanced
presentation of viral antigens to T cells (54). Finally, the DCs acquire the ability to
traffic to the lymph nodes, migrate into T-cell areas and interact directly with
naive T cells (52) . Once in the T-cell areas, mature DCs present antigen to naive
T cells, which then initiate a program of proliferation and maturation (62) . This
results in a massive increase in the number of antigen-specific T cells and the
production of large numbers of effector cells with the capacity to lyse infected
epithelial cells and secrete antiviral cytokines (70) . Finally, these effector cells
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acquire the capacity to traffic and subsequently move to the site of infection in
the lung where they effectively terminate the infection (70).
Animal models
Experimentally, the mouse model that is so familiar to immunologists
provides a well-characterized system for analyzing acute and memory responses
in this localized, non-persistent infection. Influenza can be controlled either by
CD8+ T cells or by antibodies, but mice lacking both CD8+ T cells and antibodies
succumb (19). Influenza viruses are not natural mouse pathogens, and viral
spread between mice is minimal, despite the fact that substantial lung viral titers
are achieved within 24 h of infection. Influenza infection in the ferret more closely
resembles human influenza infection, but the ferret model has received little
attention from immunologists, probably because of the lack of reagents and
inbred ferret strains.
Influenza viruses grow rapidly in the human respiratory mucosa, allowing
transmission to colleagues and family members via respiratory droplet inhalation
(coughs and sneezes) even before the development of obvious symptoms. The
net consequence is that influenza outbreaks tend to be ‘explosive’, moving
rapidly through a community, and then dying out. Any given influenza A virus
variant, however, can be sustained globally for at least 1–2 years in
geographically dispersed communities.
Therapeutics and vaccines
X-ray crystallographic analysis of the structure of monoclonal antibody–
NA complexes has helped the development of the ‘rationally designed’
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therapeutics zanamivir (Relenza) and oseltamivir (Tamiflu) (58, 97). Both
influenza A and influenza B viruses find it difficult to ‘escape’ by altering the NA
site targeted by these drugs. However, escape variants can emerge during
severe H5N1 infection (15). These drugs are being stockpiled by national
governments, but the real need is for an effective vaccine.
Adaptive immune responses to foreign antigens require precise regulation.
If not, excessive bystander damage to host tissues may occur and an unlimited
reaction could erode the size of the repertoire, limiting responses to other
antigens. It is evident that the host possesses several mechanisms that control
the size, composition and duration of immune reactions (113) . In consequence,
after the primary response most cells die leaving a memory population that
represents a fraction of the cells that responded initially to the antigen. Moreover,
these memory cells rarely account for 10% of the total antigen reactive repertoire
(1). In some circumstances, it would be desirable to expand the size of the
memory population and perhaps extend the durability of effector cell activity,
since this could improve immunity to certain pathogens. HIV is such an example
(27) .
Some bystander tissue damage usually happens since several host
defenses can destroy cells or orchestrate inflammatory reactions. With chronic
infections, for example, immune mediated tissue damage would be more severe
were it not for several cellular and chemical host components that inhibit
inflammatory reaction (72). However, the activity of some of these counter
inflammatory mechanisms could act to constrain the efficiency of protective
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immune components (78). For instance, regulatory T cells (Treg) can inhibit
inflammatory reactions associated with chronic virus infections (5), but the same
Treg response can also limit the magnitude of protective immunity to a virus or
induced by a vaccine (88, 94). Other host components may also function to limit
and help resolve inflammatory reactions. These include some cytokines (84),
groups of molecules derived from omega-3 polyunsaturated fatty acids (81), as
well as some of the carbohydrate binding proteins of the galectin family (68).
Galectin-9 (Gal-9), for example, upon binding to Tim-3 on T cells acts to limit the
extent of immuno-pathological lesions in autoimmunity (47) as well as in some
chronic infections (32, 41, 79).
Tim-3 was first discovered in 2002 as a molecule expressed on interferon
(IFN)- -producing CD4+ T helper type 1 (Th1) and on CD8+ T cytotoxic type 1
(Tc1) cells (57). The S-type lectin galectin-9 (Gal-9) was then identified as a Tim3 ligand. Gal-9 is a soluble molecule that is widely expressed, up regulated by
IFN- (3), and binds to oligosaccharides on the Tim-3 IgV domain. Gal-9
triggering of Tim-3 on Th1 cells has been shown to induce cell death (112). Thus,
Tim-3 came to be known as a negative regulatory molecule important for
abrogating Th1- and Tc1-driven immune responses. Consistent with its role as
an inhibitory molecule, blockade of the Tim-3 Tim-3L pathway in vivo by blocking
antibody or soluble Tim-3 Ig fusion protein (Tim-3Ig), which serves to block Tim3/Gal-9 interactions, exacerbates experimental allergic encephalomyelitis and
type 1 diabetes (57, 75). Similarly, abrogation of Tim-3 signaling with blocking
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antibody or by RNA interference increases the secretion of IFN- by activated
human T cells.
Tim-3 is also involved in the induction of peripheral tolerance.
Administration of Tim-3Ig abrogates the development of tolerance in Th1 cells
and Tim-3-deficient mice are refractory to induction of tolerance by administration
of high dose aqueous antigen (73). Of note, it has been shown that Tim-3 can
regulate auto- and alloimmunity by modulating the capacity of regulatory T cells
to dampen inflammatory responses (75). In addition, studies in a murine graftversus-host disease model and a hepatitis B infection model support a role for
Tim-3 in negatively regulating IFN- producing CD8+ Tc1 cells
New findings regarding the inhibitory role of Tim-3 have emerged over the past
few years and it is now well established that Tim-3 is highly expressed on
‘exhausted’ or impaired CD8 T cells in various chronic viral infections (32, 40,
41)and in tumor-bearing hosts (25, 59, 74, 111). More importantly, the function of
these impaired CD8 T cells can be restored by blocking the Tim-3/Tim-3L
pathway. Recent studies have examined Tim-3 expression in acute and chronic
models of viral infection. In acute Lymphocytic Choriomeningitis virus (LCMV)
and herpes simplex virus (HSV) infection, Tim-3 is expressed on CD8+ T cells;
however, this expression is transient and is found on only a small fraction of cells
(78). Blockade of Tim-3/Gal-9 signals during the acute phase of HSV infection
results in increased effector and memory CD8+ T cell responses and more
efficient viral control (78). By contrast, virus-specific CD8+ T cells in chronic
LCMV and Friend virus infection exhibit sustained high-level expression of Tim-3
18

on a large fraction of cells. These cells co express PD-1 and exhibit impaired
effector cytokine production (40, 89). In these experimental models of viral
infection, as well as in T cells from patients chronically infected with human

immunodeficiency virus (HIV) and Hepatitis C virus (HCV), blocking both the
Tim-3 and PD-1 pathways restores T cell proliferation and enhances cytokine
production. Thus, in chronic viral infections, both the Tim-3 and PD-1 pathways
seem to affect T cell exhaustion (Figure 3).
CONCLUSION
Understanding of the circumstances of infection and host-controlled
factors that could explain why an infection can be resolved with minimal impact
or cause substantial tissue damage could prove to be useful in the future for the
control and perhaps prevention of tissue-damaging virus infection. Accordingly by
inhibiting the factors involved in immunopathology following an acute viral
infection or manipulating the immunomodulatory factors such as some cytokines,
groups of molecules derived from omega-3 polyunsaturated fatty acids, as well
as some of the carbohydrate binding proteins of the galectin family and co
stimulatory

molecules

like

HVEM

could

be

beneficial

immunopathology and to enhance immune responses to vaccines.
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Figure. 1. Principal events in herpetic SK pathogenesis
Following ocular HSV infection replicating virus could be detected in the cornea
till 5-7 days p.i. Early inflammatory response in the cornea is dominated by the
polymorphonuclear leukocytes (PMN). Infiltration of PMNs into the cornea is be
characterized by a typical biphasic influx. Angiogenesis or the process of new
blood vessel development from the existing limbal vessels starts at 24h p.i. and
peaks around 15 days p.i. Influx of pathogenic CD4+ T lymphocytes occurs in the
clinical phase around 7-9 days p.i.
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Figure 2 | Molecular interactions between TNFRs, TNFs and immunoglobulindomain-containing receptors. Tumour-necrosis factor (TNF) receptor (TNFR)
family members predominantly interact with one or more soluble or cell-surface
TNF family ligands. Herpesvirus- entry mediator (HVEM) binds both LIGHT and
lymphotoxin-α (LTα), and LIGHT also binds LTβ receptor (LTβR) and decoy
receptor 3 (DCR3). LTα also binds TNFR1 and TNFR2. HVEM binds the
immunoglobulin-domain- containing proteins B- and T-lymphocyte attenuator
(BTLA) and herpes simplex virus type 1 glycoprotein D (HSV1 gD), whereas its
viral homologue human cytomegalovirus (CMV) UL144 binds human BTLA.
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Figure 3. Model of Tim-3 function in the immune response. (a) In acute
inflammation, Tim-3 is expressed on terminally differentiated IFN-g-producing
CD4+ and CD8+ T cells. Upon recognition of its ligand, Gal-9, Tim-3-expressing
T cells undergo apoptosis. (b) In chronic inflammation, Tim-3 is coexpressed with
PD-1 on dysfunctional or exhausted CD8+ T cells. Combined targeting of the PD1 PD-L1 and Tim-3 Tim-3L pathways successfully restores CD8+ T cell
effector function and ameliorates chronic disease. (c) Tim-3 on T cells interacts
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with Gal-9 on MDSC precursors to promote MDSC expansion, which in turn
suppresses T cell responses. (d) Tim-3 on CD4+ T cells can also act to facilitate
killing of intracellular pathogens in macrophages through interaction with Gal-9
and a mechanism involving IL-1b and caspase-1. Overall, Tim-3 on CD4+ and
CD8+ T cells harnesses multiple mechanisms to regulate negatively effector T
cell responses and terminate IFN-g-mediated inflammation while preserving or
enhancing the ability of innate cells to kill intracellular pathogens.
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PART-II
AN ANTI-INFLAMMATORY ROLE OF
VEGFR2/SRC KINASE INHIBITOR IN
HSV-1 INDUCED IMMUNOPATHOLOGY
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Research described in this chapter is a modified version of an article published in
2011 in Journal of Virology by Shalini Sharma, Sachin Mulik, Naveen Kumar,
Amol Suryawanshi, and Barry T Rouse.
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Abstract
Corneal neovascularization represents a key step in the blinding
inflammatory stromal keratitis (SK) lesion caused by ocular infection with Herpes
simplex virus (HSV). In this report we describe a novel approach to limit the
angiogenesis caused by HSV infection of the mouse eye. We show that topical or
systemic administration of the src kinase inhibitor (TG100572) that inhibits
downstream molecules involved in the VEGF signaling pathway, resulted in
markedly diminished levels of HSV induced angiogenesis, and significantly
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reduced the severity of SK lesions. Multiple mechanisms were involved in the
inhibitory effects. These included blockade of IL-8/CXCL1 involved in
inflammatory cells recruitment that are a source of VEGF, diminished cellular
infiltration in the cornea, and reduced proliferation and migration of CD4+T cells
into the corneas. As multiple angiogenic factors (VEGF, bFGF) play a role in
promoting angiogenesis during SK and since src kinases are involved in
signaling by many of them, the use of src kinase inhibition represents a
promising way of limiting the severity of SK lesions the most common cause of
infectious blindness in the Western world.

Introduction
Ocular Herpes Simplex virus (HSV) infection can result in blinding
immuno-inflammatory lesions in the cornea termed stromal keratitis (SK) (3, 25).
A critical step in the pathogenesis in SK is neovascularization of the normally
avascular cornea, but such vessels are leaky and permit the escape of cells and
inflammatory molecules into stromal tissues, events that impair vision.
Preventing, or limiting, neovascularization was shown in animal models of SK to
be a useful means to control the severity of lesions (16, 30, 31). Many molecules
may participate in causing neovascularization in the HSV infected eye, but
VEGF-A is the principal angiogenic factor involved (30). The VEGF-A can derive
from multiple sources, that include endogenous production of VEGF-A whose
angiogenic function is blocked by being bound to a soluble form of one of its
receptors (2). HSV infection results in the breakdown of this inhibitory interaction
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(26).Additional VEGF-A supplies come from newly synthesized protein by
infected or cytokine stimulated cells, as well as from VEGF-A being transported
to the eye by inflammatory cells (8). Whatever the source, VEGF-A mediates
ocular angiogenesis by signaling mainly through the VEGFR2 receptor that in
turn sets off a sequence of intracellular events that involve src kinases (6, 7, 29).
Recent studies have shown that src family of tyrosine kinases are
responsible for VEGF mediated vascular permeability and angiogenesis in several
systems (6, 11, 24).

Accordingly, using inhibitors of src kinases represents a

logical approach for therapy against pathological angiogenesis such as occurs in
SK. Approaches tested to date to inhibit angiogenesis in the SK system have either
targeted VEGF or one of its receptors, but inhibiting biochemical events set off by
VEGF signaling such as src kinase activation has not been evaluated.

This

approach could have advantages over others since src kinase are also responsible
for mediating vascular permeability and may also be involved in signaling by other
angiogenic factors, such as fibroblast growth factors (24). The later are known to
be involved in pathological angiogenesis caused by ocular HSV infection (10, 30).
Drugs have recently become available that effectively inhibit one or more
src kinases and which can function to inhibit new blood vessel development and
function (5, 19, 24). One such example is the drug TG100572, shown recently to
be effective at inhibiting VEGF mediated events involved in a non infectious
vascular disease of the retina (24). A compound of particular interest is the prodrug src kinase inhibitor TG100801, since upon topical ocular administration to the
eye it converts to the active src kinase inhibitor molecule TG100572 that inhibits
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VEGF signaling (24). In the present report, we demonstrate that TG100801 given
topically is an effective means of inhibiting neovascularization and the subsequent
severity of SK in the HSV infected eye. The use of src kinase inhibitors could add
to the arsenal of therapeutics useful for the clinical management of SK, an
important cause of impaired vision in humans.

Materials and methods
Mice and virus
Female 5-6-week-old C57BL/ 6 mice and Balb/c mice were obtained from
Harlan Sprague –Dawly (Indianapolis IN). The animals were housed in the
animal facility at the University of Tennessee. All manipulations were done in a
laminar flow hood. All experimental procedures were in complete agreement with
the Association for Research in Vision and Ophthalmology resolution on the use
of animals in research. HSV-1 RE was propagated and titrated on vero cells
(American type culture collection CCL81) using standard protocols. The virus
was stored in aliquots at -80°C until use.
Corneal HSV-1 infection and clinical observations
Corneal infections of C57BL/6 mice were conducted under deep
anesthesia. Mice were scarified on their corneas with 27 gauge needles and a 3
µl drop containing the required viral dose (104 PFU of HSV RE) was applied to
the eye. The eyes were examined on different time points post infection with a slit
lamp biomicroscope (KOWA), and the clinical severity of keratitis and
angiogenesis of individually scored mice was recorded. The scoring system was
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as follows: 0, normal eye; 1,mild corneal haze; 2,moderate corneal opacity, iris
visible; 3, severe corneal opacity, iris visible; 4, opaque cornea, ulcer formation;
and 5, necrotizing SK. Similarly, the angiogenic scoring system was based on
quantifying the degree of neovessel formation based on three primary
parameters: 1) the circumferential extent of neovessels (as the angiogenic
response is not uniformly circumferential in all cases). 2) The centripetal growth
of the longest vessel in each quadrant of the circle; and 3) the longest
neovessels in each quadrant was identified and graded between 0 (no
neovessels) and 4) (neovessels in corneal centre) in increments of nearly 0.4mm
(radius of the cornea is 1.5mm). According to this system, a grade of 4 for a
given quadrant of the circle represents the centripetal growth of 1.5mm towards
the corneal centre. The score of four quadrants of the eye were then be summed
up to derive neovessel index (range, 0-16) for each eye at a given time point.
Antibodies and reagents
For flow cytometry measurement of the infiltrating cells, 6 corneas per
group were collected at the indicated time points by dissecting the corneal
buttons above the limbus by a scalpel. Corneas were digested in liberase (Roche
diagnostics) for 45 minutes at 370C. Single cell suspension was prepared as
described elsewhere (30). The Fc receptors were blocked with unconjugated anti
CD16/32 (BD pharminogen) for 30 min. Samples were incubated with CD4-APC
(RM4-5), CD11b-PerCP (M1/70), F4/80–FITC (BM8), Gr1-PE (RB6-8C5), CD45APC (LCA-Ly5, 30-F11), CD31-PE(MEC 13.3) ,CD49d (MFR4.B) CD8-PerCP,
IFN-APC, CD44-FITC and CD62L-FITC purchased from BD pharmingen (San
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Diego, CA)

for 30 min. All samples were collected on a FACS scan (BD

biosciences) and data were analyzed using Flowjo software.
Immunofluorescent staining for PECAM-1 in vascular endothelium was also
performed on the corneal flat mounts. Corneas of Balb/c mice infected with 5x105
PFU of HSV-1 RE were dissected under stereomicroscope (Leica, Wetzlar,
Germany) and corneal flat mounts were rinsed in PBS for 30 min and flattened
on a glass slide under stereo microscope. Corneal flat mounts were dried and
fixed in 100% acetone (Sigma St. Louis, MO) for 10 min at -20oC. Non specific
binding was blocked with 10% goat serum (Sigma G 9023) for 24 hours at 4oC.
Invitrogen). The PECAM-1 was detected by an antibody directly labeled with
conjugate (PE anti mouse CD-31 MEC 13.3; BD pharmingen). Each step was
followed by three washing with PBS. Stained corneal flat mounts were mounted
with prolong gold antifade mounting reagent (invitrogen P36934) and visualized
with Nikon Ti fluorescent microscope using the software Nikon elements.
TG100801 - a topically applied prodrug form of a src kinase inhibitor was
obtained from Sanofi-Aventis (Paris)/Targegen Inc., San Diego, California. The
active compound, TG100572 (also obtained from Targegen for in-vitro use and
intra-peritoneal injections), is an ATP competitive multi targeted tyrosine kinase
inhibitor whereas the prodrug TG100801 is devoid of kinase inhibitory activity.
Treatment of animals with Src kinase inhibitor TG100801/TG100572
Female 5-6-week-old C57 BL/6 mice were used. Corneal infections were
conducted under deep anesthesia induced by i.p. injection of Avertin (Sigma
Aldrich).The mice were scarified on their corneas with a 27 gauge needle and
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infected with 104 PFU of HSV-1 RE per eye and divided randomly into groups. In
some groups src kinase inhibitor TG100801 (0.6%, 0.3%; Targegen Inc.) was
applied topically (5µl eye drop, twice daily) and in other group TG100572 (0.5,1.5
and 5mg/kg body weight dissolved in DMSO was administered intra peritoneally)
starting from either day 1 to day 14-post infection or day 6 to day 14 p.i. Animals
in the control group received liposomal vehicle (25% phospholipon vehicle 90 G)
in the case of topical drug administration and DMSO in the intra peritoneal
treatment modality following the same regimen. Mice were observed for the
development and the progression of HSK lesions and angiogenesis from day 6
until day 15 as described previously. Most of the experiments were repeated at
least 3 times unless stated otherwise.
Treatment of animals with anti VEGF antibody, Bevacizumab( Avastin)
Anti VEGF antibody Avastin was obtained from Genentech. Female 5-6wk-old C57 BL/6 mice were used. Corneal infection were conducted under deep
anesthesia induced by i.p. injection of Avertin (Sigma Aldrich).The mice were
scarified on their corneas with a 27 gauge needle and infected with 104 PFU of
HSV-1 RE per eye and divided randomly into groups. In one group src kinase
inhibitor TG100572 (5mg/kg, Targegen Inc.) was administered intra-peritoneally,
daily and in the other group Avastin (5mg/kg body weight at day 3, 6, 9 and
12p.i.) was given intra-peritoneally. Animals in the control group received mock
treatment. Mice were observed for the development and the progression of HSK
lesions and angiogenesis from day 6 until day 15 as described previously in
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materials and methods. Most of the experiments were repeated at least 3 times
unless stated otherwise.
Virus specific CD8+ IFNγ staining
To determine the immune response generated in the controls and src
kinase treated groups, intracellular cytokine staining was performed as previously
described (13). Single cell suspension of infected DLN was prepared and 106
cells per well were cultured in 96 well U bottom plates. Cells were left
untreated/stimulated with gB peptide (1 µg/ml) for 5 hrs at 37°C in 5% CO2.
Brefeldin A (10µg/ml) was added to the culture for the intracellular cytokine
accumulation. Cell surface marker and intracellular cytokine staining for IFN-γ
was performed using a cytofix /cytoperm kit (BD Pharmingen). All samples were
collected with a FACSCAN and were analyzed by FLOWJO.
Thymidine incorporation assay
Lymphocytes from the draining cervical draining lymph nodes were
obtained at day 15 p.i. and enriched for CD4+T cell population by Miltenyi biotech
CD4+T cell isolation kit. The cells were plated at the density of 5x105 in 96 well
round bottom tissue culture plate in a total volume of 200 ul of RPMI (GIBCO).
The cells were stimulated with anti-CD3 (1µg/well) anti-CD28 (1µg/well). 16
hours before harvest, [3H] thymidine (1mCi/well; 1Ci=37GBq) was added. The
cells were harvested onto-UniFilter (PerKinElmer). [3H] Thymidine incorporation
was measured in a scintillation counter and the results were expressed as mean
CPM from triplicate cultures.
Western blotting
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For the detection of FAK phosphorylation, 3 corneas per group were
dissected at the indicated time points in 300 ul of RIPA buffer containing
protease inhibitor cocktail (aprotinin, PMSF and sodium orthovanadate ), cell
debris was removed by centrifugation and the samples stored at -80oC till used
for SDS-PAGE. In brief, after 2 hrs of blocking with 3% nonfat milk in TBS,
membranes were incubated with 1:1000 dilution of rabbit polyclonal phosphorspecific anti FAK861 antibody and membranes were then incubated for 1 hr with
secondary antibody coupled to horse raddish peroxidase. Specific bands were
detected with ImmobilionTM western; Millipore). Membranes were stripped and
then reprobed to detect Total FAK and and β actin antibody.
Histopathology
For histopathological analysis, eye balls from different groups of mice
were extirpated at the indicated time point post infection in 10% formalin. In brief,
the samples were put overnight in tissue tek (Sakura), which virtually removes all
the moisture content from the samples and embeds it in paraffin. Tissue tek was
automatically programmed, that treated the samples sequentially with alcohol
(100%), xylene (100%), and paraffin. 5μm sections were then cut using
microtome and stained with hematotoxylin and eosin.
Cytokine ELISA
Six corneas per group were collected at indicated time points. The
corneas were sonicated and the levels of CXCL1/KC/mouse homologue of IL-8
were measured in the supernatants using Qantikine kit as per manufacturer’s
protocol. (R&D systems).
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Quantitative PCR (QPCR)
Total mRNA was isolated from corneal cells using TRIzol LS reagent
(Invitrogen). The cDNA prepared using 1 μg of RNA was used for subsequent
analysis. QPCR was done using SYBR Green PCR Master Mix (Applied
Biosystem, Foster City, CA) with iQ5 real-time PCR detection system. (Bio Rad,
Hercules, CA). The expression levels of cytokines were normalized to
β-actin with ∆Ct method and relative quantification between control and infected
mice was performed using the 2-∆∆Ct formula. The primers used were as follows:
IL-1β

Forward primer: CATCAACAAGAGCTTCAGGC
Reverse primer: CATCATCCCATGAGTCACAGAG

IL6

Forward primer: CCAGAGTCCTTCAGAGAGATAC;
Reverse primer: CTCCTTCTGTGACTCCAGCTTATC

IFN-γ

Forward primer: GAACGCTACACACTGCATCT:
Reverse primer: CCAGTTCCTCCAGATATCCAAG

β-actin Forward primer: CCTTCTTGGGTATGGAATCCTG,
β-actin

Reverse primer: GGCATAGAGGTCTTTACGGATG

Reverse Transcription Polymerase chain reaction (RT-PCR)
RT-PCR for the presence of CXCL1 transcripts was done according to the
manufacturer’s protocol (Promega, Madison, WI). The amplified products were
resolved on 1% agarose gel. Primers for RT-PCR were as follows.
β-actin Forward primer: CCTTCTTGGGTATGGAATCCTG
β-actin Reverse primer: GGCATAGAGGTCTTTACGGATG
CXCL1 Forward primer: GGGATTCACCTCAAGAACATCC
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CXCL1 Reverse primer: TCTGAACCAAGGGAGCTTCA
In vitro and in vivo virus (HSV-1) - drug interaction assay
The effect of src kinase inhibitor TG100572 on viral replication (if any) was
confirmed by incubating cells with inhibitor either before (pretreatment) or after
(post treatment) inoculation with the virus and then quantifying infectious HSV
kos yield by the viral plaque assay. Vero cells were infected with MOI=1 and and
were incubated with 100 nM (maximum below cytotoxicity levels) TG100572 or
0.1%DMSO either before (-1h) or after infection. The effect of the drug
(TG100572) on production of HSV-1 was determined by titrating the virus in cell
culture supernatant at different times following infection. For the in vivo assay,
the virus (HSV-RE) was quantified in eye swabs following HSV-1 infection in
TG100801 treated and control mice and titrated by viral plaque assay.
Statistical analysis
Most of the analyses for determining the level of significance were
performed using either one way ANOVA (Dunnetts post hoc test) or two way
ANOVA (Bonferroni test). Values of p≤0.001 (***), p≤0.01 (**), and p≤ 0.05 (*)
were considered significant. Results are expressed as means ± SD.

Results
Topical application of prodrug TG100801 inhibits angiogenesis and SK
The prodrug was shown by others to convert to an active inhibitor of the
src kinase involved in VEGF signaling following topical application to the eye (5,
24). Using the same conditions shown by others to inhibit retinal angiogenesis
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and vessel permeability, the effects on responses to ocular infection with HSV
was evaluated. C57BL/6 animals infected with 104 PFU of HSV-1 and divided
into 3 groups. One group served as infected and untreated control and the other
groups were treated with TG100801 either 0.3% or 0.6%, topically. Drug
treatment was administered twice daily with therapy begun 1 day after infection
until experiments were terminated on day 14 p.i. Three separate experiments
were performed and cumulated results are shown in Figs 2.1 a and b. As is
evident, there was a significant inhibition of both angiogenesis and SK lesion
severity with the higher dose of drug investigated compared to controls. The
incidence of SK as recorded in three independent experiments was lower in
TG100801 treated group (Fig 2.1c). Histological sections taken from sample
animals from test and control groups revealed evident differences in ocular
inflammatory responses (Figs.2.1 d, e &f).
In another experiment mice were infected with HSV-1 and divided into
two groups, One group was treated with TG100801 (0.6%), a concentration that
resulted in significant inhibition of both angiogenesis and SK lesion severity, and
the non treated groups receiving liposomal vehicle served as an infected control.
The corneas from these mice were collected at the indicated time points post
infection and subjected to western blotting for the detection of FAK
phosphorylation, an event known to be the biomarker of src kinase activity (6, 7,
29). Whereas phosphorylated FAK was undetectable in naïve corneal lysates, it
could be demonstrated in infected corneas as early as day 1 post infection (Fig
2.2a). However there was a significant inhibition in FAK phosphorylation in
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TG100801 treated corneal lysates at the time points tested within the periods of
elevated FAK-p861 (Fig 2.2b) suggesting that an important step in VEGF
signaling, i.e src kinase activation and FAK phosphorylation was efficiently
blocked by the inhibitor (TG100801).
TG100572 controls the lesion severity independent of viral replication
Ocular swabs from control and TG100801 treated animals, from the
above mentioned experiments were taken in the early time periods to determine
if the drug was inhibitory to virus replication. The corneas were homogenized and
centrifuged and the viral titers were determined in the supernatants of the
infected control and TG100801 treated animals. No significant differences were
observed in the viral titers recovered from the corneas in different groups (Fig 2.3
a). To measure if the src kinase inhibitors had any antiviral activity, we examined
the effect of TG100572 on HSV infection in vitro. Vero cells were infected with 1
MOI of HSV kos and treated with maximum below cytotoxic levels (100nM) of
TG100572 or 0.1% DMSO as control. Quantitation of viral titers in culture
supernatants by plaque assay revealed no significant effect on viral titers as
compared to DMSO treated controls (Fig 2.3 b). Accordingly, we conclude that
TG100572 does not have anti viral activity.
Effect of active src kinase inhibitor given systemically on ocular HSV
infection
Repeatedly administering drugs topically to the infected mouse eye can be
problematic and requires a general anesthetic to facilitate the procedure. In
consequence, experiments to measure the effects of drug treatment on cellular
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and molecular events at different times after treatment were also done in infected
animals given the active drug intra-peritoneally. Animals were ocularly infected
with HSV and divided into different groups and treated with TG100572 (0.5, 1.5
or 5mg/kg body wt) once daily starting at 24 hours after infection. The pattern of
angiogenic response, compared to sham treated controls, was recorded at day
15 p.i. Potent effects were obtained with a dose of 5mg/kg body weight (Fig 2.4a)
with minimal effects on their general health. As shown in (Fig 2.4b&c), treatment
started at day 1 p.i. (preventive) resulted in a major reduction in the extent of
angiogenesis (which was >5 fold at day 12 post infection) and SK (3 fold at day
12 p.i.) along with a 6 fold reduction in CD11b+Gr1+ cells (at day 15 p.i) (Fig 2.4
g) compared to infected and untreated control (Fig 2.4f). Additionally,
commencing treatment at day 6p.i (Fig 2.4d&e) also resulted in significant
inhibition of angiogenesis, lesion scores and CD11b+Gr1+ infiltration (Fig 2.4h)
measured at the termination of experiments at day 15 p.i. The visible
angiogenesis and SK lesion severity was also significantly less in the treated
mice (Fig 2.5a &b).
To compare our novel approach (TG100572) with a potential positive
control bevacizumab (a monoclonal antibody that binds to VEGF with high
specificity; thereby blocking VEGF mediated signaling pathways and thus
angiogenesis) (22), experiments were done where mice were divided into three
groups (n=6/group). One group received bevacizumab (Avastin) i/p (5 mg/kg body
weight) at day 3, 6, 9 and 12 p.i and other was treated with TG100572 i/p (5mg/kg
b wt) starting at day 3p.i until day 13p.i. The third group served as infected and
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untreated control. As shown (Fig 2.4i) at day 9 p.i., bevacizumab (Avastin) resulted
in significant inhibition of angiogenesis and SK severity (p<0.0201) but this was
less than observed in a group of animals that received TG100572 systemically.
TG100572 treatment showed a highly significant inhibition of angiogenesis. At day
14p.i. (Fig 2.4j) there was around 1.6 fold and 2.9 fold reduction in angiogenesis
following Bevacizumab (avastin) and TG100572 treatment respectively as
compared to the control groups.
To evaluate whether the administration of the src kinase inhibitor could
influence the expression of SK, animals were treated either with TG100572 starting
from day 1 p.i till day 14 p.i. or day 6 to day 14 p.i and the extent of inflammatory
ocular reactions were compared in the treated and control animals by sacrificing
animals and recovering ocular cells from corneas following collagenase digestion.
As is evident, there was a reduced infiltration of Gr1+CD11b+ cells (neutrophils) in
treated mice at all indicated time points post infection (Fig 2.6a). The neutrophil
infiltration peaked at day 2 and day 11 post infection in both the control and treated
mice, however the control mice had 3 fold and 2.5 fold higher frequencies (Fig
2.6a) and absolute numbers (Fig 2.6e) of neutrophil infiltrates at day 2 and day
11p.i. respectively, as compared to the treated group.
A

significant

reduction

in

the

infiltration

of

CD11b+

F4/80+cells

(macrophages) was also observed following src kinase inhibition when evaluated
at the later time points post infection (in the clinical phase). There were both
reduced frequencies (Fig 2.6b) and total numbers (Fig 2.6f) of F4/80 cells in
treated compared to the infected and untreated controls. Strikingly, around 4 fold
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decrease in the CD4+ T cells infiltration was evident in the src kinase inhibitor
treated mice both in terms of percentages (Fig 2.6c) and absolute numbers (Fig
2.6g) at the clinical phase of the disease. Additionally, the frequencies and
numbers of IFNγ+ CD4+ T cells were reduced 7-8 fold as a consequence of
TG100572 treatment along with a highly significant reduction in IFNγ and IL-2
producing CD4+ T cells upon stimulation with anti-CD3 anti-CD28 (Figs 2.7a, b, e
&f) or uv inactivated HSV kos (Fig 2.7c, d ,g & h). Corneal single cell suspension
stained for CD45 (a pan leukocyte marker) revealed significantly reduced
frequencies (Fig 2.6d) and absolute numbers (Fig 2.6h) of CD45+T cells (almost 2
fold) in the corneas of the treated mice at all indicated time points analyzed post
infection. Taken together our data indicates that both topical and systemic
administration of small molecule inhibitors of src kinases results in significant
reduction in both the extent of neovascularization and severity of SK.
Inhibition of src activity blocks CXCL1 and proinflammatory cytokines
Our observation that src kinase inhibitors caused a reduction in neutrophil
infiltration could mean that the drug inhibited the expression of molecules
involved in neutrophil recruitment such as the chemokine CXCL1. In support of
this CXCL1 mRNA was present in the infected eye at higher levels than the
scarified controls. Fig 2.8a depicts the expression of CXCL1 in HSV-1 infected
corneas as early as day 1 p.i. For the quantification of CXCL1 gene expression,
mice were ocularly infected with HSV and 6 corneas from each group (control
and treated) were collected, pooled and were analyzed by QPCR at indicated
time points. Corneas from src kinase treated mice subjected to QPCR revealed a
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decrease in CXCL1 levels at all time points tested with maximum reduction
observed during the clinical phase of the disease (Fig 2.8b). In addition, the
same situation was evident with the protein levels measured by ELISA. The
corneal supernatants were assayed for CXCL1/IL-8 by ELISA as indicated in
materials and methods. Fig 2.8c depicts the kinetics of CXCL1 protein
expression levels in the control and src kinase inhibitor treated mice throughout
the course of ocular infection. There was a significant reduction in the CXCL1 at
day 2 and also during the clinical phase (around 8 fold reduction at day 11 p.i.) of
the disease in the treated mice. Thus, our data could mean that Src kinases may
regulate critical “downstream” signaling pathways that might contribute to
expression of CXCL1, a pro-angiogenic and pro-inflammatory chemokine in
murine cornea. Additionally treated mice represented diminished levels of
proinflammatory cytokines notably IL-6, IFN-γ and IL-1β as compared to infected
and untreated controls (Fig 2.8d).
TG100572 may down regulate CD49d on CD4+T cells in lymphoid organs
resulting in fewer cells to migrate to the ocular site
SK is well known to be orchestrated by CD4+T cells (25). The frequencies
and absolute numbers of CD4+ T cells recovered by collagenase digestion of
corneas were diminished in TG100572 treated animals at all time points tested
after ocular HSV infection. To address the cause of reduced CD4+T cells in the
treated mice, animals that were ocularly infected and begun TG100572 treatment
i/p at day 1 p.i and continued daily were sacrificed and the phenotype of CD4+T
cells isolated from the DLN as well as from corneal lesions after collagenase
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digestion was evaluated at indicated time points (day 5, 7,9,11 post HSV-1 ocular
infection). In these experiments, lesion severity was greater in the control
animals as compared to the drug treated animals. FACS analysis revealed that
whereas there was no difference in the expression of CD62L (data not shown)
and a modest difference in the expression of CD44 (Fig 2.9b), interestingly
CD49d on CD4+T cells in CLN (Fig 2.9a) and corneas (Fig 2.9c) was significantly
down regulated at all time points in the src kinase inhibitor recipients. This
observed down regulation of CD49d on CD4+T cells could be relevant since
previous studies indicate that blocking CD49d reduces SK (27). Taken together,
we interpret these observations to mean that src kinases are involved in
controlling the expression of integrin molecules such as CD49d that are involved
in migration of inflammatory cells to the ocular lesion site (10) which could
explain the overall impaired infiltration of CD4+T cells in the cornea.
TG100572 inhibits CD4+T cell proliferation in vitro
Src knockout mice have shown marked reduction in inflammatory
responses to a variety of physiological insults (11). Measurement of the absolute
numbers of draining cervical lymph node (CLN) cells revealed diminished
numbers of total lymph node cells (Fig 2.9d) and also CD4+T (Fig 2.9e) cells in
the kinase inhibitor (TG100572 i.p) recipient mice at all the time points tested.
This likely means that in addition to effects on VEGF, TG100572 may also
interfere directly with CD4+T cell activation and proliferation. To explore this
possibility, draining CLN cells from HSV infected mice at day 15 p.i were
enriched for CD4+T cells and stimulated with anti-CD3 anti-CD28 (as described
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in materials and methods). In some wells, different concentrations of TG100572
(non cytotoxic concentrations) were added and the effects on proliferation
responses recorded. Whereas a minimal proliferation was observed with antiCD3 alone, anti-CD3 anti-CD28 resulted in a significant CD4+T cell proliferation.
TG100572 inhibited CD4+T cell proliferation in a dose dependent manner (Fig
2.9f) suggesting that by diminishing immune activation and CD4+T cell
proliferation,

TG100572

may

additionally

serve

to

limit

the

size

of

immunopathogenic CD4+T cells involved in lesion expression.

Discussion
Neovascularization of the otherwise avascular cornea represents a
pathological hallmark of ocular HSV-1 infection. Present approaches for clinical
management of corneal neovascularization rely on anti-virals, corticosteroids or
anti VEGF antibody treatment. In this study we show that a small molecule
inhibitor of src kinases, results in suppression of angiogenesis and lesion severity
in

a

murine

model

of

SK.

Administered

topically

as

a

prodrug

(TG100801) or the active form (TG100572) systemically, resulted in inhibition of
several key events in the pathogenesis of SK. These included diminished cellular
infiltration in the corneas, of CD4+T cells and neutrophils, the cells primarily
involved in SK. There was also a reduction in levels of the chemokine CXCL1
and proinflammatory cytokines such as IFNγ, IL1Β and IL-6. Importantly
treatment resulted in inhibited FAK phosphorylation in the corneal tissues; an
essential step in VEGF mediated angiogenesis (1). Additionally TG100572
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administered systemically resulted in down regulation of CD49d on CD4+T cells
in the DLN and cornea. However, the src kinase inhibitor had no demonstrable
proinflammatory effect and failed to express antiviral activity.
The current anti-angiogenic approach shows effective control of newly
proliferating vascular endothelial cells and since the phosphorylation of FAK and
src activation appears to be very early events post infection, src blockade by the
inhibitors early during the course of infection could be advantageous for
significant and complete anti angiogenic effects. Additionally achieving
efficacious drug concentration in the corneal tissues following the topical delivery
route (TG100801) is generally considered a technical challenge. However recent
clinical trials with these drugs have shown that TG100801, while lacking anti
kinase activity of its own, quickly generated active TG100572 within the eye upon
topical delivery, however neither compound was detectable in plasma, indicating
that delivery to the eye occurs by local penetration and not systemic absorption
(5).
Systemic treatment with the src kinase inhibitors also significantly
reduced angiogenesis and cellular infiltration, particularly of neutrophils, one
plausible explanation being that by inhibition of FAK phosphorylation, src kinase
inhibitors preserves the junctional integrity of the endothelial cells (14) and thus
inhibited the paracellular transport of neutrophils. However, src kinases were also
shown to modulate the expression of the pro angiogenic neutrophil attracting
chemokine CXCL1/mouse KC/homologue of IL8 (28) and that src kinase
activation correlates with the amount of IL-8 produced (14, 17, 28). Consistent
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with this, src kinase inhibitors resulted in inhibition of CXCL1 expression. Thus it
is possible that significant reduction in the neutrophils in the treated group may
be a consequence of reduced chemokine levels, which is the prominent regulator
of neutrophil infiltration into the inflamed cornea (23).
In humans, SK may lead to permanent loss of vision and the current
treatment modalities that are used for the clinical management of SK includes
anti VEGF antibody treatment such as bevacizumab (4, 23), antivirals and
corticosteroids but none of them are considered ideal. Antiviral compounds that
block virus entry or reduce viral replication can be prophylactic and may not be
efficacious against SK. As a result, small-molecule inhibitors targeting cellular
responses that contribute to disease may have a substantial advantage over
antiviral approaches. Corticosteroid therapy, on the other hand when continued
for a longer duration might exhibit several side effects (15), and anti VEGF
antibody

(bevacizumab)

although

shown

to

reduce

VEGF

induced

neovascularization (22, 23), however abnormal vascular permeability is
frequently associated with neovascularization (24). Thus, an antivascular
permeability compound that is also antiangiogenic such as src kinase inhibitor
should have added therapeutic benefit. Endothelial cell barrier functions are
disrupted by a number of viruses and a very recent study suggests that VEGFR2
and SFK inhibitors may be of therapeutic utility in stabilizing vasculature during
viral infections(9) .Additionally both VEGF and FGF growth factors have been
shown to be potent proangiogenic factors in HSV-1 induced corneal
neovascularization. The binding of angiogenic growth factors (VEGF, bFGF) to
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their receptors is known to result in activation of non receptor tyrosine kinases
(src kinases) which in turn regulates endothelial cell proliferation, migration and
survival (by inhibiting apoptosis of endothelial cells) (6). A compound that inhibits
redundant pathways of angiogenesis has the potential of being therapeutically
advantageous (24). In support of this our results clearly indicate that
bevacizumab (avastin), a VEGF antagonist, inhibit HSV-1 induced corneal
neovascularization, but the levels of inhibition achieved were less than that
caused by TG100572. Although we do not preclude the possibility that the
observed lesser reduction in angiogenesis in the avastin treated mice could be
due to a weaker binding affinity of avastin to mouse VEGF-A (4, 23). Our findings
therefore rationalize testing of these kinase inhibitors for additional indications
and clinical application in reducing HSV induced immunopathology. The fact that
VEGFR2 and SFK inhibitors are already FDA approved for use in humans, they
could be immediately rationalized for use in clinical cases of HSK.
A significant anti-angiogenic and anti-inflammatory effect was also
observed following systemic treatment with TG100572. This mode of treatment
also produced additional effects such as CD49d expression (on CD4+T cells) and
attenuation of T cell function. It may be argued that these effects might be due to
the limited specificity of the src kinase inhibitors (20). However the drug was well
tolerated systemically with no adverse effects on the general health except for
some reduction in the body weight of the animals. Our observations that
systemically administered TG100572 influences the severity of SK lesions is
supported by the observation of significantly less CD4+T cell infiltration in the
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cornea in the clinical phase suggesting that TG100572 (src kinase inhibitor, i/p)
could control the lesion development by limiting the migration of pathogenic T
cells to the extra lymphoid inflammatory site. The SK model represents a
situation

where

normally

immunoprotective

CD4+T

cells

exert

an

immunopathological function in the cornea of the eye(18). The Integrin CD49d
(VLA-4) is known to be involved in the migration of pathogenic CD4+Tcells to the
ocular site and that in SK 70–80% of corneal T cells in disease expresses CD49d
(VLA-4) early in lesion development (27). Thus, it was intriguing to observe that
the CD49d integrin was expressed on a significantly lower percentage of
lymphoid CD4+ T cells in the src kinase inhibitor treated mice compared to
controls. The down regulation of CD49d in src kinase inhibitor treated mice was
not unexpected since there is mounting evidence that α4 integrins use the src
family kinases to transduce intracellular signals (21). Our observations could
shed light on the relative merits of various cellular targets as candidates for
therapeutic intervention during an ongoing immune-inflammatory reaction such
as is SK. Src kinase inhibition also resulted in a less activated phenotype of
CD4+T cells as shown by decreased CD44 expression on cells in the draining
cervical lymph nodes. Additionally src kinase inhibitors resulted in diminished
levels of inflammatory cytokines which is in accordance with findings that the
reduction in proinflammatory cytokines

resulted in impairment of Th1

differentiation(12).
In conclusion, we demonstrated that the blockade of Src kinase activation
(which is an essential step in VEGF signaling) with VEGFR2/src kinase inhibitor
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resulted in reduced SK lesion severity and diminished cellular infiltration,
probably by inhibition of vascular leak and removal of a corneal chemokine
gradient. In the present approach, which is novel for infectious ocular
angiogenesis, we did achieve highly significant but not complete anti
angiogenesis. We advocate that combining src kinase inhibitor with additional
therapeutic approaches could be valuable for use in the clinic to manage herpetic
ocular lesions.
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Figure 2.1 Effect of topical administration of src kinase inhibitor
(TG100801) on the severity of SK
C57BL/6 animals infected with 104 PFU of HSV-1 were treated with TG100801
(0.3%, 0.6%, topically). TG100801 was applied topically starting at day 1 till day
14 post infection (p.i.). (a,b) Cumulative data of angiogenesis (a) and HSK scores
(b) at day 12 p.i as measured by slit lamp biomicroscopy, of three independent
experiments. The level of significance was determined by one-way ANOVA using
Dunnett’s post hoc setting. (c) The bar diagram demonstrates the percentage
severity of each group of mice infected with 104 PFU of HSV-1 RE at day 15 p.i.
in three independent experiments. The SK scores of three or greater than three
were counted as SK incidence (black bars= infected control; white bars
represents TG100801 treated). (d-f) H&E staining of the corneal sections of
naïve (d) control (e) and TG100801-treated animals (f).
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Figure 2.2 TG100801 inhibits FAK-y861 phosphorylation in the murine
cornea
(a) Western blot analysis for phosphorylated FAK861 in corneal cell lysate at
different time points following HSV-1 infection. (b) Inhibition of FAK
phosphorylation: Mice were infected with 104 pfu of HSV-1 RE. Twenty four hrs
following infection, one group was treated topically (cornea) with a 5µl drop of
0.6% TG100801, twice daily till 14 dpi. Second group received the vehicle control
in the same way. Corneal cell lysate was used to detect level of phosphorylated
FAKY861 by anti-rabbit FAK antibody in Western blot. Drug treated mice showed
inhibition of FAK phosphorhylation at all time points tested within the periods of
elevated phoshorylated FAK. (N=naïve;C=control;T=treated).
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Figure 2.3 TG100572 controls SK lesion severity independent of viral
replication
(a) Viral titers in corneal swabs in control and TG100801 treated mice at day 2
and 4p.i. is shown. (b) Vero cells were infected with MOI=1 and incubated with
100 nM of TG100572 (maximum below cytotoxicity level) after infection or
0.1%DMSO. The effect of the drug (TG100572) on production of HSV-1 was
determined by titrating the virus in cell culture supernatant at different times
following infection.
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Figure 2.4 Effect of systemic administration of src kinase inhibitor
(TG100572) on angiogenesis and SK lesion severity
(a) C57BL/6 animals infected with 104 PFU of HSV were treated with different
concentrations of TG100572 (0.5, 1.5 and 5 mg/kg body weight), intraperitoneally daily starting from either 24 hrs post infection (preventive) or day 6
p.i. (therapeutic manipulation) until day 14. The comparative angiogenesis scores
of HSV infected animals at day 14, treated with indicated concentrations of
TG100572. The statistical significance was determined using one way ANOVA.
(b-e) Kinetics of angiogenesis and lesion expression in control and TG100572
treated animals at 9-15 dpi is shown. Disease progression in control and
TG100572 treated mice following infection with 104 pfu of HSV-1 to C57Bl/6
animals under preventive (b & c) and therapeutic (d & e) mode of treatment. The
level of significance was calculated by two way ANOVA. (i & j) Comparative
angiogenesis scores in bevacizumab and TG100572 treated mice compared to
infected but untreated controls at day 9p.i (i) and day 14 p.i (j). The statistical
significance was determined by student’s t test. (f-h) Infiltration of CD11b+Gr1+
polymorph nuclear neutrophils in the corneas of control (f), following preventive
(g) and therapeutic (h) treatment at day 15 p.i. All experiments were repeated at
least three times.
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Figure 2.5 Representative eye photograph (at day 15 p.i.) of control (a) and
TG100572 treated (b) mice.
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Figure 2.6 Kinetics of Cellular infiltration in the corneas of control and
TG100572 treated mice.
Effects of TG100572 treatment on kinetics of cellular infiltration in corneas of
HSV infected animals analyzed by flow cytometry. C57BL/6 infected with 104
PFU of HSV were either treated with TG100572 5 mg/kg body weight i/p daily
starting from 24 hr p.i. until day 14p.i. or untreated controls. Single cell
suspension of the infected corneas were prepared from pooled 6 corneas (n=3)
at indicated time points from each group (TG100572 treated or control) of mice.
The cells were labeled for: (a, e) Gr1+CD11b+ (polymorph nuclear cells), (b, f)
CD11b+F4/80+ (macrophage), (c, g) CD4+ and (d, h) CD45+ (leucocyte common
antigen; pan leucocyte marker). The numbers on the dot plots indicates the
percentage of the cells expressing the particular markers in control and kinase
inhibitor treated mice at indicated time points p.i. The experiment was repeated
three times and data are representative of a single experiment.
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Figure 2.7 TG100572 treatment diminishes the infiltration of pathogenic
Th1 cells in the cornea.
C57BL/6 infected with 104 PFU of HSV-1 was treated with TG100572 (5 mg/kg
body weight) i/p daily staring from 24 hr p.i. until the termination of the
experiments. Single cell suspension of the infected corneas were prepared from
pooled 6 corneas at day 15 p.i. from each group (control and treated) of mice.
The cells were stimulated with either anti-CD3 anti-CD28 or UV inactivated HSV
Kos and stained for CD4+T cells producing IFN and IL-2. Frequencies (a & b)
and absolute numbers (per cornea) (e & f) of IFNγ+ and IL2+ T cells respectively
in control and treated group was observed following stimulation by anti-CD3 antiCD28. The frequencies (c & d) and absolute numbers (g & h) of IFNγ+ and IL2+
T cells respectively in control and treated group following stimulation by UV
inactivated HSV Kos is shown. The experiment was repeated three times and
data are representative of a single experiment.
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Figure 2.8 TG100572 treatment results in the blockade of CXCL1 in the
cornea.
(a) Agarose gel analysis for CXCL1 (132bp) (Lane 4) transcripts from infected
corneas is shown. Lane M is Marker; lane 2 is beta actin (92bp). Lane1 and lane
3 are RT negative control for beta actin and CXCL1 respectively. Lane 5 is
negative control (water) (b) Kinetic analysis for the expression of CXCL1 mRNA
by QPCR at different time p.i after src kinase inhibitor or mock treatment is
shown. WT mice were infected with HSV and treated with mock or TG100572. 6
Corneas were harvested from respective groups at an indicated time points,
pooled and subjected to quantification by QPCR for CXCL1 mRNA. (c)
Quantification of CXCL1 protein in HSV-1 infected corneas by ELISA after mock
or TG100572 treatment is shown. At each time point, 6 corneas were harvested
from HSV infected mice treated with mock or TG100572 and levels of CXCL1
protein were determined by ELISA. The level of significance was determined
using two way ANOVA with Bonferroni post test. (d) Reduction in IL6, IFN-γ and
IL-1β after TG100572 treatment is shown. The mice infected with HSV were
treated with mock or TG100572 and corneas collected from respective groups at
an indicated time points were subjected to QPCR for IL-6, IFN- and IL-1
mRNAs. The values are represented as fold change m RNA compared to
infected control. The above experiments were repeated three times.
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Figure 2.9 Src kinase inhibition may result in the attenuation of T cell
function
(a) Kinetic analysis of CD49d expression on the CD4+T cells in the control and
treated animals after ocular HSV-1 infection. C57BL/6 mice were infected with
104 PFU of HSV. Mice (n=3) were sacrificed at each indicated time points and
their draining cervical lymph nodes and corneas were analyzed for surface
expression of CD4 and CD49d by flow cytometry. (a) Histograms representing
the percentage of CD49d expression on CD4+T cells in draining cervical lymph
node at the indicated time points post infection. Data are shown from one
representative experiment. (b) Reduced expression of CD44 on CD4+T cells in
draining CLN of TG100572 treated mice. (c) FACS plots showing the percentage
of CD4+ CD49d+ T cells in the corneas in control and TG100572 treated animals
at day 11-post infection. All kinetic experiments were repeated at least twice. (d,
e) Absolute numbers (x106) of the total lymph node cells and (d) and CD4+T cells
(e) in control and treated animals is shown at indicated time points p.i. The level
of significance was determined using two way ANOVA with Bonferroni post test.
(f) DLN cells were enriched for CD4+Tcells and stimulated with anti-CD3 antiCD28 in the presence or absence of drug at the indicated concentrations. Cell
proliferation results are expressed as mean CPM from triplicate cultures.
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PART-III
TIM-3/GALECTIN-9 INTERACTION
REGULATES INFLUENZA A VIRUS
SPECIFIC HUMORAL AND CD8 T CELL
RESPONSES
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Research described in this chapter is a modified version of an article published in
2011 in in Proc. Natl. Acad. Sci. USA. by Shalini Sharma, Aarthi Sundararajan,
Amol Suryawanshi, Naveen Kumar, Tamara Veiga Parga, Vijay K Kuchroo, Paul
G Thomas, Mark Y Sangster and Barry T Rouse.

Shalini Sharma, Aarthi Sundararajan, Amol Suryawanshi, Naveen Kumar,
Tamara Veiga Parga, Vijay K Kuchroo, Paul G Thomas, Mark Y Sangster and
Barry T Rouse. Tim-3/Galectin-9 interaction regulates influenza A virus specific
humoral and CD8 T cell responses. pnas.org/cgi/doi/10.1073/pnas.1107087108.

In this chapter “our” and “we” refers to co-authors and me. My contribution in the
paper includes (1) Selection of the topic (2) Compiling and interpretation of the
literature (3) Designing experiments (4) understanding the literature and
interpretation of the results (5) providing comprehensible structure to the paper
(6) Preparation of graphs and figures (7) Writing and editing.

Abstract
Reactions to pathogens are usually tuned to effect immunity and limit
tissue damage. Several host counter inflammatory mechanisms inhibit tissue
damage but these may also act to constrain the effectiveness of immunity to
acute infections, as we demonstrate in mice acutely infected with influenza A
virus (IAV). We show that compared to wild type (WT), galectin-9 knockout
(G9KO) mice mounted a more robust acute phase virus-specific CD8 T cell
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response as well as higher and more rapid virus specific serum IgM, IgG and IgA
responses, and also cleared virus more rapidly than did WT mice. Blocking
galectin-9 signals to Tim-3 expressing cells using a Tim-3 fusion protein resulted
in improved immune responses in WT mice. When IAV immune mice were
challenged with a heterologous IAV, the secondary IAV-specific CD8 T cell
responses were 4-5 fold higher in G9KO compared with WT mice. Our results
indicate that manipulating galectin signals may represent a convenient approach
to improve immune responses to some vaccines.

Introduction
The host immune response to pathogens needs precise regulation to
minimize tissue damage whilst still achieving defense (24, 39). Some bystander
tissue damage usually happens since several host defenses can destroy cells or
orchestrate inflammatory reactions. With chronic infections, for example, immune
mediated tissue damage would be more severe were it not for several cellular
and chemical host components that inhibit inflammatory reactions (24). However,
the activity of some of these counter inflammatory mechanisms could act to
constrain the efficiency of protective immune components (27). For instance,
regulatory T cells (Treg) can inhibit inflammatory reactions associated with
chronic virus infections (1), but the same Treg response can also limit the
magnitude of protective immunity to a virus or induced by a vaccine (32, 34).
Other host components may also function to limit and help resolve inflammatory
reactions. These include some cytokines (31), groups of molecules derived from
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omega-3 polyunsaturated fatty acids (29), as well as some of the carbohydrate
binding proteins of the galectin family (22). Galectin-9 (Gal-9), for example, upon
binding to Tim-3 on T cells acts to limit the extent of immuno-pathological lesions
in autoimmunity (14) as well as in some chronic infections (7, 9, 28). In the
present study, we investigated whether the inhibitory effects of Gal-9 on Tim-3
expressing cells could influence the outcome of acute infection with IAV. We
demonstrate that animals lacking the regulatory effects of Gal-9/Tim-3 triggering
mount superior CD8 T cell and humoral immune responses and were more
refractory to IAV. Moreover, IAV immune G9KO mice challenged with a
heterologous IAV strain generated better virus-specific memory CD8 T cell
responses then WT animals. Our results indicate that manipulating galectin
signaling may represent a convenient approach to improve responses to some
vaccines.

Materials and Methods
Mice and virus infections
Female 6-8-wk-old C57BL/6 were purchased from Harlan SpragueDawley and housed in the animal facilities at the University of Tennessee,
Knoxville. G9KO were kindly provided by Gal Pharma Co. Ltd, Japan. Stocks of
IAV strains HK/x31 (H3N2)(x31) and A/Puerto Rico/8/34 (H1N1)(PR8) for mice
infections were grown and titrated as described previously (11). Mice were
infected intranasally with 5000 EID50 of IAV HKx31 in 30-µl volume. To assess
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secondary CD8T cell responses, mice were infected with x31 and challenged
intranasally at least 4 weeks later with 8000 EID50 of PR8. The Animal Care and
Use Committee of the University of Tennessee approved all animal procedures.
Tissue sampling
Spleen, BAL fluid, plasma and lung samples were recovered from mice at
acute phases of the primary and secondary infections. BAL samples were
obtained from individual mice as described previously (20). Cells in the BAL were
collected by centrifugation and the supernatants were stored at -80°C for ELISA.
BAL associated cells were pooled from three mice in each group and single cell
suspensions were prepared from individual spleens. IAV x31 titers in lungs were
determined by plaque assay using MDCK cells (15).
Flow cytometry
The antibodies to CD8 (53-6.7), CD4 (RM4-5), CD62 ligand (CD62L)
(MEL-14), CD44 (IM7), IFN, TNFα, IL-2, and CD103 (2E7) were purchased from
BD Bioscience. PE and APC conjugated Tim-3 antibodies were purchased from
R&D Systems. Intra-nuclear FoxP3 staining was performed using a kit from EBioscience according to the instructions. Cell suspensions were blocked with
anti-mouse CD16/32 and then incubated with specific antibodies or isotypes for
30 min at 4°C. The antibody-stained cells were acquired with a FACS Calibur (BD
Biosciences) and the data were analyzed using the FlowJo software (Tree Star,
OR).
Tetramer and phenotypic staining of CD8 T cells
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Influenza

A

peptide

NP366–374

(ASNENMETM),

NP311–325

(QVYSLIRPNENPAHK) were kindly provided by the Trudeau Institute and Dr.
John Altman respectively. The experiments utilized the H-2Db MHC class I
glycoprotein

complexed

with

the

influenza

virus

nucleoprotein

(NP)

ASNENMETM peptide (NP) and being designated NPtet and staining was done
as described previously (17). H-2Db-NP366–374 is an immuno-dominant CD8 T cell
response to IAV in H-2b mice (35). IFN and TNFα producing T cells were
enumerated by ICCS as previously described (16). In brief, 106 freshly isolated
splenocytes were cultured in U bottom 96-well plates. Cells were left untreated or
stimulated with NP366-374 ASNENMETM peptide (0.1µg/ml or 0.02µg/well),
NP311–325 QVYSLIRPNENPAHK (10µg/ml or 2µg/well), and incubated for 5 h
at 37°C in 5% CO2. Brefeldin A (10 µg/ml) was added for the duration of the
culture period to facilitate intracellular cytokine accumulation. After this period,
cell surface staining was performed, followed by intracellular cytokine staining
using a Cytofix/Cytoperm kit (BD PharMingen) as per the manufacturer’s
recommendations. The fixed cells were re-suspended in FACS buffer (PBS with
3% heat inactivated serum) and analyzed flow cytometrically.
Ex vivo apoptosis assay
Spleen single cell suspension isolated 10 days pi from IAV infected
animals were incubated for 5 hrs with varying concentrations of Gal-9 in the
absence or the presence of α lactose in 96-well flat-bottom plates in humidified
incubators in the presence of 5% CO2. After the incubation period was over, cells
were stained for annexin V using a kit from BD Biosciences. Additionally, cells
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were also co-stained for CD8, Tim-3, DbNPTet. Stained cells were analyzed
immediately by flow cytometry.
ELISA
Virus-specific antibodies levels in plasma and BAL were determined by
ELISA using plates coated with purified, detergent disrupted virus (25). The
antibody titer is expressed as the reciprocal of the highest dilution giving an
absorbance value more than twice that for simultaneously titrated samples from
naive mice.
Quantification of IAV in infected lung tissue
The quantification of IAV (HKx31) in lung tissue was done as previously
reported (15). Briefly, Lungs were removed from infected mice on days 2,4,7,8, 9
and 10 days after infection and snap-frozen in serum free minimal essential
medium (MEM) supplemented with 0.2% bovine serum albumin, 20 mmol/L
Hepes, 100 U/ml penicillin, and 100 mg/ml streptomycin. Snap-frozen lungs were
stored at -80°C until further processing. Tissues were disrupted by chopping with
scissors, homogenized and centrifuged at 10,000 rpm for 15 minutes. The
resulting supernatant was used to titrate the virus on MDCK cells as follows:
Serial 10-fold dilution (in MEM) of the virus was incubated on 90-100% confluent
MDCK cells for 1 hr. Thereafter, the infection medium was replaced with 2 ml of
agar-overlay medium containing equal volume of 2X L-15 medium (Invitrogen)
and 2% agar (Becton Dickinson). The plates were further incubated at 37oC. The
plaques were visible at 3 days post-infection which were counted following
staining with 0.2% crystal violet. The 2X L-15 medium contained 27.4g L-15
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powder (2 bags), 0.25% Bovine serum albumin, 2X L-glutamine (Invitrogen), 2X
Penicillin and streptomycin (Invitrogen), 2X HEPES (Invitrogen), 2X nonessential
amino acids (NEAA) (Invitorgen) 0.15% sodium bircarbonate and 2 mg/ml TPCK
treated trypsin (Life Technologies, Inc., Grand Island, NY).
Immunoblotting

for

the

detection

of

galectin-9

expression

and

quantification
Mediastinal Lymph node (MLN) and lung homogenate samples (10
mg/lane) were resolved on 15% SDS-PAGE and transferred electrophoretically
on to a PVDF membrane (Bio-Rad). The membrane was blocked overnight with
5% BSA and washed 5 times with TBS containing 0.05% Tween-20 (TBST) and
incubated with biotinylated anti- galectin antibody (R&D Systems) at a
concentration of 0.5 mg/ml diluted in TBST for 1 hr at room temperature. The
membrane was washed 5 times with TBST and incubated with streptavidin- HRP
antibody (Pierce) at a dilution of 1:10000 for 1 hr at room temperature. The
membrane was developed with chemiluminescent substrate (Immobilon western
chemiluminescent HRP substrate, Millipore) and the image was taken on CLXPosure X-ray film (Thermo scientific).
Ninety-six-well microplates were coated with capture antibody at a
concentration of 3000 ng/ml (100 ml/well, anti-galectin-9, GalPharma Co. Ltd,
Japan). After incubation overnight at 4⁰C, the wells were washed three times with
PBST (PBS containing 0.05% Tween-20) and blocked with 5% BSA for 2 h at
RT. The wells were washed three times with PBST and Lymph node, spleen
homogenate samples (100 ml) were added to the wells and incubated at RT for 2
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h and aspirated. The wells were then washed with wash buffer. Biotinylated anti
galectin detection antibody (1;10000, R&D Systems) diluted in reagent diluent
(R&D Systems, PBS, 5% Tween 20, 2% goat serum) was added to each well
and incubated at RT for 1 h. The wells were then washed three times and 100 ml
of streptavidin–horseradish peroxidase (1:10000 dilution) added and incubated
for 1 hr at room temperature. The plate was washed thrice and developed with
TMB (R&D systems) substrate and the absorbance of each sample was
determined at 450 nm. A standard curve ranging from 5 mg to 156.25 ng of
recombinant galectin-9 (Gal Pharma, Japan) was generated to calculate the
galectin-9 concentration in the unknown samples.
In vivo blockade with Tim-3 fusion protein
For blockade of Tim-3 pathway, 100 µg Tim-3 Ig fusion protein were
injected intra peritoneally on alternate days starting from day 1 until the time of
sampling on day 10 p.i.
Adoptive transfers
Splenocytes from WT or G9KO (both Thy1.2) x31 immune mice were
enriched (miltenyi biotech kit) for CD8 T cells and then titrated for 104 NPtet+ CD8
T cells and transferred into Thy1.1 C57BL/6 animals. Alternatively 104 NPtet+
CD8 T from B6Thy1.1 (x31 immune) mice were transferred into Thy1.2 C57BL/6
WT or G9KO animals. 24 hrs post transfer, recipient animals were infected with
8000 EID50 PFU of IAV PR8. 8 days post challenge CD8 T cell analysis was
performed.
Statistical analysis
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Data were analyzed using Prism 5.0 software (Graph pad). Experiments
were repeated two to three times. The data presenting the differences between
the groups were assessed using two-tailed unpaired student’s t tests or by two
way ANOVA with Bonferroni post hoc settings. Values of p< 0.001 (***), p< 0.01
(**), and p< 0.05 (*) were considered significant. P<0.05 indicates that the value
of the test sample was significantly different from that of relevant controls.

Results
Virus-specific CD8 T cells up regulate Tim-3 expression after IAV infection
Both BAL and spleens were isolated at different times from IAV infected
WT animals and analyzed by FACS for CD8 T cells that expressed Tim-3. The
highest levels in the BAL were observed at day 8, with 30-40% of total CD8 T
cells expressing Tim-3 (Fig 3.1A). In addition, most of these Tim-3+ cells were
also CD44hi and CD62Llo (Fig 3.1D, upper panel) indicative of activated or
effector phenotype. Peak frequencies of Tim-3+ CD8 T cells were also present on
day 10 p.i. in the spleen (Fig 3.3J). Using tetramers and the ICCS assay to detect
DbNP366-374 (ASNENMETM) specific CD8 T cells, up to 75% IAV NP tetramerspecific cells were Tim-3+ (Fig 3.1 A and C) as well as CD44hi and CD62Llo (Fig
3.1D, lower panel). Furthermore, after NP peptide stimulation the majority
(around 75%) of IFN+ CD8 T cells were Tim-3+ (Fig 3.1B). Endogenous levels of
Gal-9 in the lung extracts of IAV infected animals were also quantified by both
western blotting (Fig 3.1E) and ELISA (Fig 3.1F). Basal levels of Gal-9 were
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detectable in control lung extracts and these were moderately increased after
IAV infection. A significant increase (2-2.5 fold) was observed at around 7 days
p.i.
We could also show at day 10p.i. that around 20-22% of total CD4 T cells
(Fig 3.1G) were Tim-3+ in the BAL samples of the WT animals. Moreover, using
the ICCS assay to detect NP311–325 (QVYSLIRPNENPAHK) peptide- specific
CD4 T cells, up to 65-70% (on average) of virus specific IFN+ CD4 T cells were
Tim-3+ (Fig 3.1H). Tim-3 expression was not detected on CD3-B220+CD19+ B
cells.
Gal-9 induces apoptosis of IAV NPtet+CD8 T cells ex-vivo
The results of previous in vitro studies revealed that Gal-9 binding to Tim3 receptors on some, although not all, T cell subsets causes them to undergo
apoptosis (28, 38).To test the fate of the CD8+Tim-3+ population following IAV
infection to Gal-9 exposure, spleen cells were collected at day 10 pi and exposed
in vitro for 5 hrs to a range of concentrations of Gal-9. Subsequently, the cells
were analyzed by FACS for changes in the expression levels of Tim-3 and
annexin V, the latter indicative of apoptosis (12).

As shown in Fig (3.2A),

approximately 16-17% of CD8+T cells were Tim-3+ at the onset of culture and this
percentage did not change significantly in the absence of Gal-9 (Fig 3.2A).
However, Gal-9 addition (at 1.0 µM) caused a loss of almost all cells that were
Tim-3+ (Fig 3.2A). Baseline levels of annexin V+ cells also did not change
significantly in the absence of Gal-9 (or in the presence of Gal-3, data not
shown). However, when optimal amounts of Gal-9 were present, annexin V+ cells
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increased 15-20% beyond baseline numbers (Fig 3.2A lower right quadrant).
This number roughly correlated with the fraction of Tim-3+CD8+T cells that
disappeared upon Gal-9 exposure.
In additional experiments, we measured the effects of Gal-9 addition on
the fate of NPtet+CD8+T cells, the majority of which, as described previously,
were Tim-3+. As shown in Fig 3.2B, the great majority of NPtet+ CD8+T cells were
lost after Gal-9 exposure and there was a notable increase in annexin V+T cells
(Fig 3.2B lower right quadrant). In other experiments with Gal-9 treated cultures,
we investigated the effects of adding an excess of a-lactose, the sugar that binds
to the carbohydrate binding domain of Gal-9 and reduces Gal-9 binding to Tim3(3, 38). In such experiments, lactose addition served to prevent the
disappearance of most Tim-3+ (Fig 3.2A) as well as NPtet+CD8+T (Fig 3.2B) cells
and also reduced the increase in annexin V+ cells. Taken together, our results
imply that Gal-9 binding to Tim-3+ effectors can cause them to die by apoptosis.
The major effect of Gal-9 was observed in Tim-3+ cells and was dose
dependent. However there was a low level of apoptosis of Tim-3- cells consistent
with recent reports that Gal-9 could regulate T cell function independently of Tim3 (30). Our ex-vivo results indicate that Gal-9 binding to Tim-3+ effectors causes
them to die by apoptosis in-vitro, an effect that might similarly occur in vivo.
Animals unable to produce Gal-9 mount better acute phase virus-specific
CD8 T cell responses
We reasoned that if the presence of endogenous Gal-9 acts to limit the
magnitude of CD8 T cell responses in the WT animals, then mice unable to
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produce Gal-9 due to gene knockout (G9KO), should respond better than WT
animals to IAV. To analyze this possibility, WT and G9KO animals were infected
intranasally with 5000 EID50 of IAV (x31) and the magnitude of CD8 T cell
responses were compared 6, 8 and 10 days later. As shown, the responses of
virus-specific CD8 T cells in both BAL and spleen, as measured by tetramers
(3.3A-E) and ICCS (3.3H-J) were significantly higher at multiple time points in the
G9KO mice. In both WT and G9KO animals up to 70-73% IFN+ CD8 T cells
were Tim-3+ (3.3I). However, a higher proportion of Tim-3+ and NPtet+ T cells in
G9KO were CD44hi (3.3K and L) and CD62Llo (3.3M and N) indicating that more
virus specific CD8 T cells in G9KO animals expressed the activation phenotype.
We also evaluated and compared the mean fluorescence intensity (MFI) of IFN
and co-expression of multiple cytokines, both indicative of high quality T cells
(26). G9KO animals expressed significantly higher MFI of IFN as compared to
WT animals (3.3F). Collectively our data indicates that G9KO animals have a
2.5-3.5 fold augmented IAV specific CD8 T cell responses that have a higher
proportion of CD8 T cells with properties of high quality.
ICCS was also performed on the BAL fluid cells using NP311-325 peptide
stimulation (to detect IAV specific CD4 T cells) at day 10p.i. G9KO mice had 2-3
fold higher frequencies of IFN+CD4 T (IAV specific CD4 T) cells in the BAL as
compared to the WT (3.3H). Additionally, around 39-40% of CD4 T cells were
Tim-3+ at day 10 p.i. in the BAL of G9KO (3.3G) compared to only 18-20% in the
WT mice. It is conceivable that better CD4 T cell responses of G9KO mice play a
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role in maintaining higher CD8 T cell responses and also provides help for
antibody (Ab) responses (33). Additionally, compared to WT mice, G9KO animals
had fewer Tregs both in the BAL (Fig3.10 A, B and C) and spleen (Fig3.10 D)
particularly that were CD103+ and Tim-3+ (Fig3.10 E and F).
Gal-9 knockout mice generate a more rapid IAV-specific humoral response
WT and G9KO mice were also compared for their serum virus-specific Ab
responses. Serum levels of virus-specific IgM and IgG were substantially higher
in G9KO compared with WT mice on day 7 (Fig 3.4 A and B), indicating a
markedly more rapid Ab response in the G9KO mice. IgG levels remained
significantly higher in G9KO mice for at least 2 wk after infection. The strong
early Ab response in G9KO mice reflected enhanced production of both the IgG1
and IgG2c isotypes, but by day 14 only IgG2c remained significantly higher in
G9KO mice (Fig 3.4 C and D). To gain further insights into the B cell response,
Ab-secreting cells (Fig 3.4 J and K) and germinal center B cells (Fig 3.4 L and M)
in the draining lymph node on day 8 after infection were identified by flow
cytometry. The proportion of cells with the B220int CD138+ phenotype of Absecreting cells was significantly higher in G9KO mice, consistent with the higher
level of circulating virus-specific Ab early in the response. Interestingly, the
proportion of PNA+ FAS+ germinal center B cells was significantly higher in WT
mice, raising the possibility that strong early Ab-secreting cell formation in G9KO
mice was at the expense of entry of activated B cells into germinal center
reactions.
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Virus-specific Ab levels were measured in the BAL to evaluate the IgA
response as well as Ab-mediated antiviral activity at the site of viral replication.
There was a trend towards higher BAL levels of IgG and IgA in G9KO compared
with WT mice on day 10, but differences were not quite significant (Fig 3.4 E and
F). An analysis of virus-specific serum Ab levels in G9KO and WT mice on day 8
after IAV PR8 infection demonstrated a much earlier response in the G9KO mice
(Fig 3.4 G and H), consistent with the result after x31 infection.
Diminished viral titers and enhanced viral clearance in Gal-9 knockout mice
To evaluate if G9KO and WT mice differed in their effectiveness at
clearing viral infection, animals were infected with 5000 EID50 of IAV (x31) intranasally and the lungs from the infected WT and G9KO mice (n=3 per group at
each time point) were collected at days 2,4,7,8 and 9 p.i. to quantify IAV. Viral
levels were similar in early lung homogenate samples but by day 7p.i. levels in
G9KO mice were significantly (p<0.05) decreased compared to WT (Fig 3.4 I).
G9KO mice cleared virus by day 8 p.i., but WT animals still possessed virus 9
days p.i. The results of viral clearance experiments clearly indicated that G9KO
animals had more effective protective immunity to IAV. Susceptibility of G9KO
mice to IAV HKx31 was also compared with WT mice by three different
approaches: body weight loss (Fig 3.7), neutrophil infiltration (Fig 3.8), and lung
histopathology (Fig 3.9). Our data indicate that G9KO showed greater weight
loss and significantly increased CD11b+Ly6G+ neutrophil infiltration at day 3p.i in
the BAL following IAV infection. By histopathology no differences were observed
at the lower viral doses, but at 5x107 EID50 multifocal type II pneumocytic
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hyperplasia was observable in at least 50% of the G9KO mice.
Gal-9 knockout mice develop more robust recall responses to IAV infection
To compare recall response to IAV, animals were primed with x31 then
challenged intranasally 41 days later with the heterologous IAV strain PR8. The
NPtet+ CD8 T cell responses were around 4-5 fold higher in the G9KO as
compared to WT animals in the BAL (Fig 3.5 A and D) and spleen (Fig 3.5 E, H
and I). Additionally G9KO mice had a 4 fold greater proportion of NPtet+ cells that
were Tim-3+ in the BAL (Fig 3.5C) and spleen (Fig 3.5G). More interestingly,
when primary and secondary responses were compared, WT mice expressed 23 fold higher frequencies of NPtet+ CD8 T cells compared to the primary
response, while in G9KO mice the NPtet+ T cell frequencies were enhanced 8
fold. Furthermore a significantly higher proportion of NPtet+ CD8 T cells were
CD62Llo (5 fold higher) in BAL (Fig 3.5B) and (9 fold higher) in the spleens (Fig
3.5F) of G9KO animals. Using the ICCS assay IFN+TNFα+ CD8 T cells in BAL
(3.5 J and K) and spleen (Fig 3.5L) in G9KO mice were increased over WT
indicative of larger and higher quality responses. The significantly higher
proportion of CD62Llo and Tim-3+ IAV NP tetramer specific CD8 T cells in the
G9KO mice that followed secondary infection suggests that a greater proportion
of these cells were in an activated state in G9KO mice during recall responses. In
an attempt to address the issue of whether G9KO CD8 T cells were intrinsically
more responsive or being less inhibited in G9KO environment, adoptive transfer
experiments were conducted (Fig 3.11A). The accumulation of WT DbNPtet+
donor Thy1.1+ CD8 T cells was significantly greater in G9KO than WT recipient
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animals (Fig 3.11 G and H) indicating that Gal9/Tim-3 signaling is responsible for
the observed T cell phenotype. The reverse experiment, where WT or G9KO
cells were transferred to WT animals resulted in no observed differences in
expansion. Taken together our results suggest that the Tim-3/Gal-9 interaction
acts in normal animals to limit the magnitude and efficiency of recall CD8 T cell
responses.
In vivo blockade of Tim-3 pathway results in augmented primary IAV
specific CD8 T cell responses
Our results indicated that Gal-9 may be playing a role in vivo to limit the
extent of anti-viral CD8 T cell responses. To further evaluate the regulatory effect
of Tim-3/Gal-9 interaction, this pathway was inhibited in vivo with a Tim-3 fusion
protein (Tim-3 Ig). Using tetramers and the ICCS assay to record virus specific
CD8 T cell responses in the BAL and spleen, Tim-3 blockade resulted in
approximately 1.6 to 2 fold higher frequencies and 4 fold higher absolute
numbers of NPtet+ and IFN+TNF+ CD8 T cells in BAL (Fig 3.6 A and B) and
spleen (Fig 3.6E) at day 10 p.i. The blockade also resulted in better viral control
(Fig 3.6C). Additionally a higher proportion of virus specific CD8 T cells were
CD62Llo both in the BAL (Fig 3.6D) and spleen of Tim-3Ig treated mice (Fig
3.6F). A similar phenotype was observed when the Tim-3 fusion protein
administration was begun at day 4p.i. (data not shown).

Discussion
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The host response to pathogens is usually tuned to effect immunity and to
minimize any bystander tissue damage resulting from the immune reaction to the
invader (24). Tissue damage is limited by several counter inflammatory events
that act to functionally inhibit or destroy damaging cells as occurs when Gal-9
binds to one of its receptors, Tim-3 (38). Counter inflammatory event benefit the
host in some chronic inflammatory processes (13, 14), autoimmunity and some
viral immunopathological lesions (28, 38) but, as we demonstrate in this report,
Tim-3/Gal-9 interactions can also act to limit the effectiveness of immunity to
acute infectious agents, such as influenza virus. Accordingly, we show that mice
lacking the ability to produce Gal-9 because of gene knockout generate more
robust anti-viral T cell responses, more rapid antibody responses and control
intranasal infection more effectively than WT animals.

The more effective

responses to IAV by G9KO animals was explained by the observation that virus
specific CD8 and CD4 T cells up regulate Tim-3 early after infection, making
them susceptible to apoptosis upon binding to Gal-9, as we demonstrated in ex
vivo studies. G9KO animals also developed better recall responses to IAV and
generated superior CD8 T cell responses compared to WT upon heterologous
IAV infection. Our results could mean that manipulating signals that are usually
provided by Gal-9 could result in improved responses to influenza vaccines.
Our data indicate that decreased cellular responses observed in WT
animals were likely the consequence of the elevated endogenous production of
Gal-9 that occurred after infection, along with the fact that most of the responder
T cells, both CD8 and CD4, up-regulated the Tim-3 receptor. This scenario would
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set the scene for T cell apoptosis as demonstrated by our ex-vivo studies.
However, alternative events might also explain the better responses of G9KO
animals compared to WT. For example, G9KO animals have lower numbers of
FoxP3 Tregs compared to WT. Such cells could be responsible for suppressing
the magnitude of influenza specific T cell responses as some have reported (8),
at least as a minor effect. In addition to the observance of 2-3 fold higher
responses in G9KO animals, on the basis of multi-cytokine production and the
levels of cytokine produced by antigen stimulated CD8 T cells (26), the
responses in GK9O mice were also of higher quality than were those in WT mice.
This may mean that the levels of Tim-3 differ between responding T cells
accounting for differential susceptibility to Gal-9 mediated killing or inhibition.
However, such effects were not formally investigated.
Whereas a number of previous studies reported the modulating effects of
Tim-3/Gal-9 on T cell-mediated lesions and immunity, few if any have analyzed
the influence on Ab responses. We show that the early production of virusspecific antibody responses to influenza infection was strikingly enhanced in the
absence of Gal-9. Since we could not demonstrate Tim-3 expression on B cells,
their destruction as a consequence by Gal-9 binding would seem an unlikely
mechanism. A better explanation may be that the enhanced responses of G9KO
animals reflected the absence of modulating effects of Gal-9 on Tim-3 expressing
helper CD4 T cells. Antibody responses to influenza virus are largely T cell
dependent (25). Thus, accelerated B cell help due to an increase in the
availability or effectiveness of CD4 T cells could explain the stronger early
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antibody responses observed in G9KO mice (18, 19). We did not evaluate CD4 T
cell activation in lymph nodes draining the respiratory tract where cognate help
for early B cell responses is delivered. However, Gal-9 deficiency resulted in
higher frequencies of virus-specific CD4 T cells in the airways after influenza
infection, consistent with a more vigorous CD4 T cell response in the draining
lymph nodes. The rapidity of the B cell response in G9KO mice suggests an
increase in antibody-secreting cell generation via the extrafollicular pathway of B
cell differentiation, an arm of the B cell response that is enhanced by increased
availability of T cell help (23). The expression of Tim-3 by activated Th1, but not
Th2, cells suggests that the Th1 response may be preferentially enhanced in
G9KO mice. This could fit with the pattern of isotype expression in the antibody
response of G9KO mice, since enhanced IgG2c production (driven by Th1-type
cytokines) was sustained for longer than was IgG1 production (driven by Th2type cytokines). We also observed that the frequency of germinal center B cells
was significantly lower in G9KO than in WT mice likely reflecting differentiation of
activated B cells via the extrafollicular pathway at the expense of germinal center
formation in G9KO mice. At this time, we cannot exclude other mechanisms that
may also contribute to the enhanced Ab response in G9KO mice. For instance
Gal-9 deficiency may limit other mechanisms of suppression (5), resulting in
increased levels of factors that act directly on B cells to promote their activation
(4).
Antiviral antibody production in response to influenza infection contributes
in large part to viral control (37). We analyzed virus-specific antibody levels in the
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airways as a measure of antibody-mediated antiviral activity at the site of viral
replication. This strategy also permitted an evaluation of the effect of Gal-9
deficiency on the virus-specific IgA response, since IgA-secreting cells generated
in lymphoid tissues rapidly home to the respiratory tract submucosa and secretes
IgA that is transported to the airway lumen (10, 25). IgG that is recovered from
the airways is thought to be primarily derived from circulating antibody by
transudation (21). The levels of virus-specific IgG and IgA recovered from the
airways on day 10 after infection were generally higher in G9KO compared with
WT mice, but differences were not quite statistically significant. However, the
overall kinetic pattern suggested earlier production of both IgG and IgA in G9KO
mice and a contribution of these antibodies to antiviral activity in the lung during
the phase of viral clearance. A strong IgA response in G9KO mice, as for the IgG
response, may reflect a more vigorous and sustained CD4 T cell response (25).
However, this mechanism must be weighed against evidence that strong Th1
responses and IFN production, as might be expected in G9KO mice, are
antagonistic to IgA production (2, 6, 36). Further studies are required to clarify
this situation.
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Figure 3.1 Tim-3 expression is up regulated on virus-specific CD8 T cells
after IAV infection:
At different time points after infection, BAL and spleen cells (n=3) isolated at
each time point were analyzed flow cytometrically for Tim-3 expression on IAV
specific CD8 T cells. BAL samples from 3 mice were pooled. (A) Percentage of
total CD8 T cells and NPtet+ CD8 T cells expressing Tim-3 in BAL is shown. (B)
FACS plots showing Tim-3+IFN+ CD8 T cells at day 10 p.i in the BAL fluid of WT
animals. (C) Frequencies of Tim-3+ NPtet+ CD8 T cells in the BAL of IAV infected
animals. (D) Co-expression of Tim-3 (upper panel) and DbNPtet+ (lower panel)
with CD44 and CD62L in BAL of WT mice at day 8 p.i. is shown by
representative FACS plots. (E) Immunoblots showing Gal-9 expression in the
lung homogenates from naïve and IAV infected mice at different time points post
infection. (F) Gal-9 concentrations as measured by sandwich ELISA using antiGal-9 mAb in the lung homogenates is shown. (G) Histograms depict Tim-3
expression on CD4 T cells in WT and G9KO animals at day 10 p.i. in the BAL.
(H) Representative FACS plots showing IFN+ Tim-3+ CD4 T cells in BAL of WT
and G9KO animals upon NP311–325 peptide stimulation. Numbers in the
quadrants indicate percent of each subset. Data are representative of three
independent experiments.
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Figure 3.2 Galectin 9 induces apoptosis of IAV NP tetramer specific and
Tim-3+ CD8 T cells in vitro:
Ex Vivo apoptosis assay was performed with Splenocytes isolated at 10 dpi from
IAV infected animals as described previously (3). Briefly splenocytes were
incubated for 5 hours with varying concentrations of galectin-9 in the absence or
the presence of α-lactose. The experiments were repeated multiple times with
similar results. (A) Representative FACS plots showing the expression of Tim-3
and annexin-V on gated CD8 T cells under indicated incubation conditions. (B)
Representative FACS plots showing the expression of NPtet and annexin-V on
gated CD8 T cells under indicated incubation conditions. (C) The bar diagram
shows the percent of Tim-3+ CD8 T cells as calculated from A (with three
triplicate wells). (D) The bar diagram shows the percentage of NPtet+ CD8 T cells
as calculated from B. Statistical analysis was done by 2 way ANOVA with
Bonferroni post hoc settings.
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Figure 3.3 Gal-9 knockout animals mount stronger virus-specific CD8 T cell
responses in the acute phase:
Virus-specific CD8 T cell responses were compared among age and gender
matched IAV infected WT and G9KO animals at indicated time points post
infection. Representative FACS plots showing NPtet+CD8 T cells from WT and
G9KO animals in the BAL (A) and spleen (B). (C) Absolute numbers of NPtet+
and IFN+TNF+ CD8 T cells at day 10 p.i. in BAL. Bar diagram shows the
frequencies (D) and absolute numbers (E) of NPtet+ CD8 T cells in spleen. (F)
The MFI of cytokine IFN produced by CD8 T cells in BAL. (G) Histograms
showing Tim-3 expression on total BAL CD8 T cells in WT (light line) and G9KO
mice (darker line) at day 10p.i. Representative FACS plots show the frequencies
of Influenza A peptide NP366–374 (ASNENMETM) stimulated polyfunctional
(IFN+TNFα+) CD8 T cells isolated from the BAL (H, upper panel) and spleen (H,
lower panel) at day 10 p.i. of WT and G9KO animals. (I) Tim-3 expression by
IFN+CD8 T cells in WT and G9KO animals at day 10 p.i following stimulation
with NP366-374 peptide. (J) Absolute numbers of Tim-3+, IFN+, IFN+TNF+ CD8 T
cells in the spleen at indicated time points p.i. Co-expression of Tim-3 and NPtet+
with CD44 in BAL (K), spleen (L) and with CD62L in BAL (M) and spleen (N) at
day 8 p.i. is shown in WT and G9KO animals by representative FACS plots. Data
are representative of three independent experiments with 3 mice per group in
each experiment. Error bars represent SEM.

110

111

112

Figure 3.4 Enhanced virus-specific antibody production in G9KO mice after
influenza infection.
(A-F) WT and G9KO mice were sampled on the indicated days after intranasal
infection with influenza X31. Plasma levels of virus-specific IgM (A), IgG (B),
IgG1 (C), and IgG2c (D), and BAL levels of virus-specific IgG (E) and IgA (F)
were measured by ELISA. Titers are expressed as the reciprocal of the endpoint
dilution and are shown as mean + SE for 6-8 individual mice in each group. (G,
H) Plasma levels of virus-specific IgM (G) and IgG (H) on day 8 after intranasal
infection with influenza PR8. The mean + SE is shown for 6-8 individual mice in
each group. Arrows indicate values below the level of assay sensitivity. (I) 0n
indicated days post infection, lungs from WT and G9KO mice were collected and
assayed for influenza viral titer by viral plaque assay. Representative FACS plots
(J) and bar graphs (K) depicting the frequencies of CD3-B220+CD138+ B cells in
the MLN of WT and G9KO mice at D8 p.i. Representative FACS plots (L, upper
panel= naïve; lower panel= day 8p.i) and bar graphs (M) showing CD3B220+PNA+FAS+ germinal center B cells in the MLN of WT and G9KO mice.
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Figure 3.5 Gal-9 knockout mice develop more robust recall responses to
influenza A virus upon heterologous challenge:
Both WT and Gal-9 KO animals primed 41 days previously with x31 were
challenged intranasally with 8000 EID50 of heterologous IAV (PR8) and the
response in the BAL and spleen measured at day 8-post challenge by tetramers
and ICCS assays. Representative FACS plots showing the frequencies of NPtet+
CD8 T cells in the x31 immune WT and G9KO animals in BAL (A) and spleen (E
and H) respectively. Absolute numbers of NPtet+ CD8 T cells in BAL (D) and
spleen (I). Co-expression of NPtet and CD62L in BAL (B) and spleen (F). Tim-3
expression on NPtet+ CD8 T cells isolated from BAL fluid (C) and spleen (G) of
WT and G9KO animals. Representative FACS plots showing the frequencies (J)
and absolute numbers (K) of IFN+TNF+ CD8 T cells at day 8 post challenge in
the BAL of x31 immune WT and G9KO animals. (L) Absolute numbers of
IFN+TNF+ CD8 T cells in the spleen of x31 immune WT and G9KO animals.
Data are representative of three independent experiments. Error bars represent
SEM.
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Figure 3.6 Administration of Tim-3 fusion protein in mice after IAV infection
enhances the magnitude and quality of IAV-specific CD8 T cells responses.
IAV infected C57BL/6 animals were treated with 100µg of Tim-3 fusion protein
per mice from day 1 post infection at alternate days until day 9 p.i. and those in
the other group were given control Ig and animals were sacrificed at day 10 p.i
Percentages (A) and absolute numbers (B) of NPtet+ and IFN+ TNF+ CD8 T
cells isolated from the BAL of Tim-3 fusion protein treated and control animals
are shown. (C) Viral titers in the lungs of control and Tim-3 Ig treated mice. (D
and F) Co-expression of NPtet and CD62L on CD8 T cells in BAL and spleen
respectively is shown. (E) Absolute numbers of NPtet+ CD8 T cells isolated from
the spleen at day 10 p.i. Data are representative of three independent
experiments with three to four mice per group. Error bars represent SEM.
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Figure 3. 7 Outcome of infection with IAV HKx31:
WT mice were inoculated with IAV HKx31 (108, 107, 106, 105, 104 EID50 or PBS).
(A) Body weight of WT mice after infection was determined daily and expressed
as the percentage of the body weight lost following infection. (B) % body weight
loss comparison between the WT and G9KO mice infected with 5000 EID50 i/n.
over a period of 10 days is shown. (C) % body weight loss comparison between
the WT and G9KO mice infected with 5x107 EID50 i/n. over a period of 10 days is
shown. The data are representative of 5-6 mice per group.
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Figure 3.8 Cells obtained from broncho-alveolar lavage (BAL) were stained for
CD45+ (pan leukocyte marker) and CD45+CD11b+Ly6G+ (neutrophils) and FACS
analysis performed at day 3 (A and B) and day 7 (D and E) in WT and G9KO
mice. Bar graphs representing % CD45+CD11b+Ly6G+ (neutrophils) at day 3p.i
(C) and day 7p.i. (F) is shown. The experiments were repeated multiple times
and the data are representative of pooled BAL samples from 3 mice. Statistical
analysis was done by student’s t test and the Error bars represent SEM.
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Figure 3.9 Lung histopathology: The lungs of mice infected with 5000 EID50 of
virus were harvested at indicated time points post infection, washed in PBS, fixed
in 10% neutral buffered formalin and embedded in paraffin wax. Sections (5 mm)
were stained with haematoxylin and eosin and microscopically reviewed. H&E
sections from WT (A) and G9KO (B) animals infected with 5000EID50 of IAV x31
at day 9 p.i is shown. Representative H&E sections from WT (C) and G9KO (D)
animals infected with 5x107EID50 of IAV x31 at day 10 p.i is shown. The section
blocks in the upper right corner represent the 40X magnification. The overall lung
readouts (n=3 mice at each time points/group infected with x31 5000 EID50) is
indicated as table E.
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Figure 3.10 Characterization of CD4+FoxP3+ regulatory T cells from WT and
the G9KO mice:
C57BL/6 and G9KO animals were infected intra-nasally with 5000 EID50. BAL
samples from 3 mice were pooled and spleens from individual mice were stained
for FoxP3. Representative FACS plots show the frequencies of FoxP3+ Tregs in
the BAL (A) and spleens (D) of WT and G9KO animals at day 10 p.i. The kinetics
of Treg frequencies at indicated time points p.i. (B) and their absolute numbers at
day 10 p.i (C) in the BAL fluid of WT and G9KO is shown. Histograms showing
the expression of Tim-3 (E) CD103 (F) and CD44 (WT-light line) and (G9KO-dark
line) (G) on FoxP3+ Tregs isolated from the Spleens of WT and G9KO animals at
day 10 p.i.
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Figure 3.11 Adoptive transfer of memory CD8 T cells: Splenocytes from
either WT or G9KO (both Thy 1.2) HKx31 immune mice (mice were held for at
least one month following infection with IAV HKx31 i/n) were enriched for CD8T
cells using miltenyi biotech (CD8T cell isolation) kit. Around 93-94% pure CD8T
cells were obtained in the enriched CD8T cell population. The enriched CD8T
cells were then titrated for equal number of NP tetramer specific CD8T cells and
1x104 antigen specific CD8T cells were transferred in B6 Thy1.1 mice (n=4).
Alternatively splenocytes from B6 thy1.1 HKx31 immune mice (mice were held
for at least one month following infection with IAV HKx31 i/n) were enriched for
CD8T, and equal number of NP tetramer specific CD8T cells (1x104) cells were
transferred in WT or G9KO mice (n=4). 24 hrs post transfer, the recipients were
challenged with 8000EID50 of heterologous IAV (PR8). (A) Diagrammatic
depiction of the scheme for adoptive transfer experiments. (B) Representative
FACS plots for enriched CD8T cell population is shown. FACS plots show the
frequencies of donor Thy1.2+CD8+ (C, upper panel) and NPtet+ Thy1.2+ CD8+ (C,
lower panel) WT or the G9KO cells in the MLN (C), and spleen (D) of Thy1.1
animals at 8dpi. Absolute numbers of the donor NPtet+thy1.2+CD8+T cells WT or
the G9KO cells in the MLN (E) and spleens (F) of the recipients. Absolute
numbers of the donor NPtet+Thy1.1+CD8+T WT or the G9KO cells in the MLN (G)
and spleens (H) of the recipients are shown. The experiments were repeated two
times. Statistical analysis was done by student’s t test and the Error bars
represent SEM. (I) Representative histograms showing CD62L expression by
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NPtet+ CD8 T cells in the MLN’s of WT and G9KO animals at day 23 p.i. (J) Bar
graphs represents the ratios of CD62Lhi/CD62Llo of NPtet+ CD8 T cells in the
MLN of WT and G9KO animals at day 23 p.i.
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PART-IV
REGULATORY T CELL EXPRESSION OF
HERPES VIRUS ENTRY MEDIATOR
(HVEM) FOLLOWING HSV-1 INFECTION
AND ITS FUNCTIONAL SIGNIFICANCE
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Research described in this chapter is from a manuscript that is in preparation for
submission to Journal of Immunology by Shalini Sharma and Barry T. Rouse.

Sharma S and Rouse BT. Regulatory T cell expression of Herpes virus entry
mediator following HSV-1 infection and its functional significance. (Journal of
Immunology-in preparation).

In this chapter “our” and “we” refers to co-authors and me. My contribution in the
paper includes (1) Selection of the topic (2) Compiling and interpretation of the
literature (3) Designing experiments (4) understanding the literature and
interpretation of the results (5) providing comprehensible structure to the paper
(6) Preparation of graphs and figures (7) Writing and editing.

Abstract
In many infections especially those that are chronic, the outcome may be
influenced by the activity of one or more types of regulatory T cells (Tregs).
Infections may cause Treg expansion but how this is accomplished remains
uncertain. In this report, we demonstrate one possible mechanism by which
HSV-1 infection could act to signal and expand the Treg population. We show
that CD4+FoxP3+ regulatory T cells up regulate the receptor, herpes virus entry
mediator (HVEM) following HSV-1 infection [a binding site for major viral
glycoprotein HSV-1gD (gD)]. Recombinant HSV-1 gD added to the cultures
increased the proportions of Foxp3+ cells among CD4+CD25+T cells, up
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regulated activation markers on FoxP3+ T cells in the cultures and expanded
Treg population with suboptimal TCR stimulation. The Treg expansion was
dependent on gD interaction with HVEM. In addition Treg expansion in HVEM
knockout animals (HKO) was significantly less than WT mice. As a result HKO
animals generated more elevated T cell responses than the wild type (WT)
animals and cleared virus more rapidly. Our results are discussed in terms of
understanding of the factors that control Treg activation and expansion in
response to pathogens and their application to manipulate Treg function in acute
infections.

Introduction
The magnitude of a T cell mediated immune response to an acute viral
infection may be influenced by the activity of one or more types of regulatory T
cells (15), particularly those that express FoxP3. Pathogens may signal Treg
expansion with the response influencing the magnitude and perhaps pattern of
the immune response. In some cases, responses to pathogens and vaccines are
elevated if the Treg response is modulated (14, 17). The extent of the Treg
response in different individuals may also explain in some circumstances the
differential outcome of infection with chronic infection such as in hepatitis(4).
However in situations where infections persist and immune reactions cause
extensive tissue damage such as HSK, the Treg response can be beneficial and
can limit the size of lesions (10). In many studies the Treg response to pathogens
is assumed to consist mainly or predominately of antigen specific Tregs, although
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there are instances where the Treg involved appear not be antigen reactive. This
may be the case with HSV infection, and this possibility is investigated in the
present report. We show that one of the major glycoprotein of HSV, normally
involved in viral entry into susceptible cells, may cause proliferation and
activation of Treg since such cells may express the entry molecule HVEM.
Besides being an entry receptor for HSV, HVEM is identified as a co-stimulatory
molecule that is known to be constitutively expressed on the cells of the immune
compartment. HVEM can promote T cell activation by propagating signals from
the TNF super family member ligand, LIGHT, a lymphotoxin related inducible
ligand (19) that competes with glycoprotein D for binding to HVEM on T cells or
can deliver inhibitory signals upon binding with BTLA (B and T lymphocyte
attenuator). In a previous report HVEM knockout mice were shown to develop an
unexpected enhancement of T cell responses (18), with increased susceptibility
to autoimmunity. In addition over expression of HVEM enhances Treg
suppressive function (16) suggesting a role of HVEM in Treg suppressive
function.
Our studies demonstrate that a CD4+FoxP3+ regulatory T cell expand and
up regulate HVEM following HSV-1 infection. Additionally HSV-1gD was
detectable in the draining popliteal lymph nodes (PLN) following footpad infection
with peak levels present around day 5 p.i. Primed cells, when re-stimulated with
UV inactivated HSV resulted in further upregulation of HVEM on Tregs.
Interestingly the presence of soluble gD increased the proportions of Foxp3+ cells
among CD4+CD25+T cells in the culture and expanded Tregs in the presence of
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suboptimal TCR stimulation. Consistent with this, HKO mice possessed
significantly diminished ratios of CD4+FoxP3+/CD4+FoxP3- cells in the PLN after
HSV-1 infection and cleared virus faster than the WT animals. This could mean
that engagement of HVEM with gD results in Treg activation and expansion
which in turn modulates effector responses. T cells from scurfy mice, which have
truncated form of FoxP3 (16) lacked HVEM expression even after activation and
over expression of HVEM enhances Treg suppressive function (16) suggesting a
role of HVEM in Treg suppressive function. Consistent with this, naïve HVEM
knockout animals expressed reduced frequencies and expression levels of
FoxP3+ T cells compared to their naïve WT counterparts.

Materials and Methods
Mice and Virus
Female 7-8-wk-old C57BL/6 (B6) (H-2b) mice were purchased from
Harlan Sprague-Dawley and housed in the animal facilities at the University of
Tennessee. Foxp3-GFP knock in mice were a kind gift from Dr. M. Oukka
(Brigham and Women’s Hospital, Harvard Medical School). HVEM knockout mice
were obtained from Dr. Carl Ware at La Jolla institute of Allergy and Immunology
(LIAI), California and were bred and maintained in the animal facility at the
University of Tennessee. All investigations follow guidelines of the Committee on
the Care of Laboratory Animals Resources, Commission on Life Science,
National Research Council. HSV-1 strain KOS and RE was grown in vero cells
obtained from American Type Culture Collection. The viruses were concentrated,
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titrated, and stored in aliquots at -80C until use. Titers were measured in vero
cells and expressed as PFU per milliliter. Mice were infected in footpad (FP) with
2.5 x 105 PFU of HSV KOS in 30-µl volume. Corneal infections of C57BL/6 mice
were conducted under deep anesthesia. Mice were scarified on their corneas
with a 27-gauge needle, and a 3 µl drop containing the required viral dose was
applied to the eye. The eyes were examined on different days post infection (dpi)
with a slit-lamp biomicroscope (Kowa), and the clinical severity of keratitis and
angiogenesis of individually scored mice was recorded as described elsewhere
(12).
Antibodies and Reagents
Antibodies purchased from BD PharMingen were PerCP-CD4, FITC and
PE anti-FoxP3, APC–anti-CD25 (PC61), APC-anti-CD103, FITC-anti GITR,
antiCD62 ligand (CD62L), FITC-anti-CD44, and PerCP-anti-CD69. BrdU staining
kit was purchased from BD Pharmingen. PE- anti HVEM (e-Bioscience),
recombinant HSV-1gD and anti HVEM antibody were kindly provided by Dr. Gary
Cohen (University of Pennsylvania), Recombinant human IL-2 was obtained from
Hemagen. Complete RPMI 1640 was used for in vitro cultures.
Quantitation of HSV-1 in Foot Pad Tissues
The quantitation of HSV-1 in foot pad (FP) tissue was determined as
reported by Jennings et al (5). Briefly, the mice were killed at the indicated time
post infection (p.i.), the FP surface was cleaned with 70% isopropyl alcohol, and
the tissues were removed with a scalpel. The tissues were stored in virus diluent
(PBS supplemented with 0.6 mM CaCl2, 0.5 mM MgCl2/H2O, 20 mg Phenol red,
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and 50g gentamicin sulfate per ml) at -80⁰C. Tissues were disrupted by
homogenization in 1 ml ground glass grinders (Wheaton) and centrifuged, and
the supernatant was used to assay viral titration on vero cells. Finally, plaques
were visualized with crystal violet.
Cell Surface and Bromodeoxyuridine Staining
Surface staining was performed as described previously (6). For
bromodeoxyuridine (BrdU) staining, the BrdU kit from BD PharMingen was used
according to the manufacturer’s instructions. Briefly, HSV-1 infected mice
received i.p. injection of BrdU (1 mg/ml) 12 hours before termination of mice.
Draining popliteal lymph node cells were stained first with anti-CD4 and FoxP3
and subsequently labeled with anti-BrdU mAb. Samples were analyzed on a
FACS caliber cytometer using FlowJO software (BD Biosciences).
Western blotting
For the detection of HSV-1gD, draining popliteal lymph nodes were
dissected at the indicated time points in 300 ul of RIPA buffer containing
protease inhibitor cocktail (aprotinin, PMSF and sodium orthovanadate), cell
debris was removed by centrifugation and the samples stored at -80oC till used
for SDS-PAGE. In brief, after 2 hrs of blocking with 3% nonfat milk in TBS,
membranes were incubated with 1:1000 dilution of rabbit polyclonal anti HSV1gD antibody (mouse monoclonal IgG1, 100 µg/ml, Santa Cruz biotechnology)
and membranes were then incubated for 1 hr with secondary antibody coupled to
horse raddish peroxidase. Specific bands were detected with ImmobilionTM
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western; Millipore). Membranes were stripped and then reprobed to detect 
actin.
Cell purification and in vitro cell culture
CD4 T cells were purified from Foxp3-GFP knock-in animals using a CD4
T cell isolation kit, and 5x105 cells were cultured with the indicated
concentrations of recombinant HSV-1gD and suboptimal concentrations of antiCD3. In some cultures anti-HVEM antibody was added to the cultures. In
additional experiments FoxP3+ cells were sorted (FACS vantage) from the
enriched CD4 T cell population based on the GFP expression. CD4+FoxP3+
Tregs were incubated with recombinant HSV-1gD. 48 hours post incubation
Tregs in the culture were analyzed by flow cytometry for expression of surface
activation markers.
Thymidine incorporation assay
Splenocytes from the naïve FoxP3-GFP knock in mice were enriched for
CD4 T cells using CD4 T cell isolation kit according to the manufacturer’s
protocol (Miltenyi Biotec, Auburn, CA). Tregs were sorted (FACS vantage) from
this enriched CD4 T cell population based on GFP expression. Sorted
CD4+CD25+ Treg populations were incubated with anti-CD3 and recombinant
HSV-1gD at the indicated concentrations. The cells were plated at a density of 5x
105 in 96-well round-bottom tissue culture plates in a total volume of 200 l of
RPMI medium (Gibco). Sixteen hours before harvest, [3H] thymidine (1µCi/well;
1Ci=37GBq)

was

added.

The

cells
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were

harvested

onto

a

UniFilter

(PerkinElmer). [3H]thymidine incorporation was measured with a scintillation
counter, and the results were expressed as mean cpm from triplicate cultures.

Results
HSV infection causes expansion of FoxP3+ Tregs
To follow changes in CD4+FoxP3+ Treg responses after HSV
infection, FoxP3GFP knock in mice were used and analyses were performed in
draining PLN populations. The infection changed the frequency of CD4+T cells
that were FoxP3+ with numbers of such cells increased by more than two fold at
day 5 p.i (fig 4.1B) and more than fourfold at day 8 p.i. compared to naive mice.
A similar trend was observed with the absolute numbers of CD4+FoxP3+. The
absolute numbers of CD4+ T cells (fig 4.1C) in the popliteal lymph nodes peaked
at day 5 p.i. Whereas the highest absolute numbers of CD4+FoxP3+ cells (fig
4.1D) were present after the peak of effector activity i.e. at day 8 p.i. To
determine whether or not different viral loads could influence the magnitude of
Treg expansion, we infected WT animals with various inoculation doses of HSV-1
i.e 2x106, 2x105, 2x104 as well as with UV inactivated virus. Increasing infection
doses resulted in a gradual increase in the level of Treg expansion in the draining
popliteal lymph nodes (data not shown).
HVEM expression is up-regulated on regulatory T Cells following HSV-1
infection
We next analyzed the expression of HVEM on Tregs. HVEM, a tumor
necrosis factor receptor super family member that interacts with the gD protein of
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HSV-1 to facilitate cell entrance, is shown to be constitutively expressed by the
cells of the immune compartment. Flow Cytometry showed HVEM expression by
45-50% of naïve CD4+FoxP3+ cells. Following HSV-1 infection in the footpad,
HVEM was up regulated on CD4+FoxP3+ cells with up to 70% at day 8p.i and
90% CD4+FoxP3+ cells expressing HVEM at day 11p.i (fig 4.2 A and B). The MFI
of HVEM expression was also increased on FoxP3+ Tregs (fig 4.2C) following
HSV-1 infection. HVEM knockout Tregs have been reported to be less
suppressive and over expression of HVEM in Tregs increases their suppressive
ability (16) thus increased expression of HVEM on Tregs following HSV-1
infection could be of functional significance.
In some experiments DLN cells from infected FoxP3-GFP knock in mice
were obtained at indicated time points post infection and were stimulated with
either UV inactivated HSV kos or anti-CD3/anti-CD28 for 72 hours. HVEM
expression was analyzed on CD4+FoxP3+ and CD4+FoxP3- cells by flow
cytometry. Our results demonstrate that HVEM expression was further up
regulated (fig 4.3A) on FoxP3+ CD4 T cells when stimulated with UV inactivated
HSV kos but not on CD4+FoxP3- cells. Stimulation with anti-CD3 anti-CD28 did
not result in change in HVEM expression levels on either the FoxP3+ or FoxP3cells (fig 4.3B). Interestingly the highest MFI of HVEM expression after UV
inactivated HSV stimulation was observed when the cells were obtained after day
6 p.i. Taken together our in vivo observations of the detectable HSV-1gD in the
DLN after HSV-1 infection and in vitro experiment suggests that presence of
HSV-1 gD could influence the up regulation of its own receptor HVEM.
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It has been shown that HSV-1 is able to enter activated T lymphocytes as
well as immature and mature DCs. Additionally gD is expressed on the surface of
infected T cells and it is postulated that the cellular gD interacts with HVEM in a
juxtacrine and autocrine way (7). To explore the mechanism that might be
responsible for triggering Treg expansion, we hypothesized that possibly HSV
itself could trigger this and may represent an early means by which the virus
infection could signal Treg activation and expansion. Experiments were
performed to detect if viral protein gD is detectable in the draining lymph node.
Western blotting on the draining popliteal lymph node homogenates from the
naïve and HSV infected animals at day 2, 5, 7 and day 10 p.i. showed that
whereas the PLN homogenates from the naïve mice completely lacked gD
expression and a negligible amounts of gD was detectable at day 2 p.i. However
gD was detectable at day 5, 7 and 10 post HSV-1 infection, a significant
expression of gD being detectable in the PLN homogenates at days 7 and 10 p.i.
(fig 4.3C).
Recombinant HSV-1 gD increases the proportions of FoxP3+ T cells among
CD4+CD25+T cells
Our observations that regulatory T cells expand following HSV-1 infection,
that HVEM is preferentially up regulated by regulatory T cells and more
interestingly the detectable levels of HSV-1 gD in the draining popliteal lymph
node led us to hypothesize that the interaction of HVEM with one of its known
viral ligand gD could be of functional significance in terms of causing a T cell
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perhaps only Treg to change gene expression, proliferate or show activation
changes.
To address this question we performed three sets of experiments, in one
experiment we enriched CD4 T cells (fig 4.4A) from the splenocytes of naïve
mice (up to around 90% purity) and incubated 5x105 cells with varying
concentrations of recombinant gD and anti CD3 (1 ug/ml). As shown in fig 4.4B,
addition of recombinant gD in the presence of anti-CD3 increases the proportion
of FoxP3+ cells among the CD4 T cells in the cultures. This effect was relatively
specific for HSV-1gD HVEM interaction, as addition of anti HVEM antibody to the
cultures did not result in increased proportions of FoxP3+ cells (fig 4.4C). In some
experiments FoxP3+ cells were sorted from enriched CD4 T cells based on GFP
expression and 2x105 FoxP3-GFP+ cells were incubated with different
concentrations of HSV1-gD and IL-2. 48hrs post-incubation, the cells were
stained for activation markers. CD69 and CD25 were up regulated on Tregs that
were incubated with recombinant gD in a dose dependent manner (fig 4.4 D and
E). In the third set of experiments sorted FoxP3+ cells (2x105 cells) were
incubated with anti-CD3 alone or anti-CD3 plus recombinant HSV-1 gD and
recombinant IL-2 in the cultures. In presence of gD, Tregs showed proliferation
when relatively higher concentrations of anti-CD3 was used (fig 4.5C). This
proliferative effect was not observed when anti-HVEM antibody was added (fig
4.5D) to the culture suggesting an effect that is mediated by gD binding with
HVEM. Taken together our results could mean that besides being an entry
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receptor for HSV, HVEM binding with HSV-1 gD can trigger activation and
proliferation of Tregs.
HVEM knockout mice generate weaker Treg responses
Our in-vivo and in-vitro observations suggest that HVEM is up regulated
on regulatory T cells following HSV-1 infection and that gD-HVEM interaction
results in the increased representations of CD4+FoxP3+ regulatory T cells among
CD4 T cells. To evaluate if HKO and WT animals showed differences upon HSV1 infection, the animals were infected with HSV-1 in the foot pad and the
frequencies and absolute numbers of CD4+ and CD4+Foxp3+ cells were recorded
in the draining popliteal lymph node at day 5.5 and 8p.i. At day 5.5 and day 8 p.i
HKO mice had significantly reduced frequencies of CD4+Foxp3+T cells (fig 4.6 CF). The absolute numbers of total lymphocytes (p<0.0006) as well as CD4+T cells
(p<0.0006) and CD4+FoxP3+Tcells (p<0.017) were significantly higher in the
HKO animals (fig 4.7A). The numbers sustained to be significantly higher for CD4
T cells (p<0.0179) even at day 8 p.i in the HKO mice. These findings are
consistent with the previous findings (18) that reported a hyper proliferative CD4
T cell responses in HKO mice. However when the representation of CD4+FoxP3+
among the CD4+FoxP3- T cells was compared, HKO mice showed a significantly
lower Treg to Teff ratios at day 8 p.i (p<0.002) (fig 4.7 D and E), whereas the
ratios were largely non significant at day 5.5 p.i. consistent with our observations
that significantly higher numbers of CD4+FoxP3+ T cells are observed after the
peak of effector responses in the WT animals. Taken together and consistent
with in vitro experiments, our in vivo data suggests that there are diminished
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representations of CD4+FoxP3+ regulatory T cells among CD4 T cells in the HKO
mice. The expansion of Tregs observed in the draining popliteal lymph node
following HSV-1 infection might be mediated by recruitment and/or proliferation of
these cells. BrDU incorporation assay was performed to analyze whether Treg
undergo proliferation in vivo. HSV-1 infected mice were pulsed with BrDU 12
hours before sacrifice. At day 8 p.i. draining popliteal lymphoid populations were
analyzed by FACS for evidence of BrDU incorporation. CD4 T cells were gated
on FACS plot, and the assay revealed an average 1.5 to 2 fold increase in
proliferation of CD4+FoxP3+ cells in PLN of WT animals compared to HKO (fig
4.6 G and H).
Additionally the proportions of CD4+T cells co expressing FoxP3 and the
activation markers CD25 (fig 4.8A, B and E), CD103 (fig 4.8C, D and F), were
significantly reduced in HKO animals. Interestingly a higher proportion of FoxP3+
cells were CD62Llo (fig 4.8G) at the indicated time points post infection and
reduced expression of CD44 on FoxP3+ cells (fig 4.8H and I) in HKO mice
compared to the WT animals, thus indicative of them being less activated.
Influence of regulatory T cell expression of HVEM on the outcome of
immune response to HSV
We monitored whether the diminished representations of FoxP3+ T cells in
HKO mice affected the course of viral infection. Our data imply that the acute
cutaneous viral load in the FP was comparable in both WT and HKO until day 5
However, no viral plaques were observed in the HKO mice on day 6 whereas
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significant viral load was still present in the control animals. By day 8 no virus
was detected in the FP of both groups (data not depicted).
In the mouse model of SK, CD4+CD25+ regulatory T cells have been
shown to control the severity of viral immuno-inflammatory lesions (14) and
previous studies have suggested a non-redundant inhibitory effect of HVEM on T
cell responses (18).Thus given our data that HKO Tregs are less suppressive
and the lack of HVEM mediated negative regulation of T cell activation we tested
the susceptibility of HKO mice to the development of HSK following ocular HSV-1
infection. There were two possibilities, either the HKO mice will not develop the
disease because they lack the HSV-1 entry receptor (HVEM) or will develop
more disease due to the deficiency of negative regulatory interaction.
WT or HKO mice were infected with 1x104 PFU of HSV RE ocularly and
the progression of HSK and angiogenesis were recorded by slit lamp
biomicroscopy. The cellular infiltration in the collagenase digested corneas was
recorded at day 15 p.i in WT and HKO animals. There were around 2 fold higher
frequencies of CD4 T (fig 4.9A) cells with significantly increased expression of
CD49d (fig 4.9B) on them in the HKO animals compared to the WT animals.
These findings are consistent with our own findings where absence of Tregs
resulted in altered phenotype of CD4 T cells (with increased CD49d expression
on CD4+T cells) following ocular HSV-1 infection (14).

Discussion
To survive an infection, host needs to generate an efficient immune
response against the pathogen but at the same time the host immune response
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to pathogens needs precise regulation to minimize tissue damage whilst still
achieving defense (10). Tregs play a very important role in balancing these 2
contradictory effects occurring in most infectious diseases. In our previous report
we have shown that HSV infection activates and expands CD4+CD25+ regulatory
T cells (15) and the majority of expanded Tregs are not antigen specific. In the
current study we report one possible mechanism by which HSV-1 infection could
act to signal and expand the Treg population. Using footpad infection model we
show that CD4+FoxP3+ regulatory T cells up regulates HVEM following HSV-1
infection and the viral ligand HSV-1gD was detectable in the draining popliteal
lymph nodes (PLN). Presence of recombinant HSV-1 gD increased the
proportions of Foxp3+ cells among CD4+CD25+T cells and up regulated activation
markers on FoxP3+ T cells in the cultures. Consistent with this, HKO mice
represented significantly diminished ratios of CD4+FoxP3+/CD4+FoxP3- cells in
the PLN after HSV-1 infection and cleared virus faster than the WT animals
suggesting that functional interaction of HSV-1gD with HVEM expressed on T
regs might be one possible means of non-specific Treg expansion.
In the present study we observed significantly increased frequencies and
absolute numbers of FoxP3+ Tregs following HSV infection of the footpad in the
draining PLN. These findings are consistent with our previous report (15)
suggesting that the CD8 T cell response to the immunodominant peptide
SSIEFARL was significantly enhanced when CD4+CD25+ Tregs were depleted.
Treg activation prevents immunopathology by dampening pathogen specific
immune responses but this can also lead to enhanced pathogen survival (3). This
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leads to the question for the cells or the factors involved in expansion of Treg and
whether proliferation, de novo induction or enhanced survival of Tregs is the
predominant reason for the increased numbers of Tregs in the virus infected
tissues and the draining lymph nodes following a viral infection. It has been
reported that virus infected DCs can expand the population of FoxP3+ cells in
vitro upon presentation of antigens to naïve T cells (2), alternatively it is shown
that CD8+T cells play a vital role in Treg expansion (22, 23) where Friend’s virus
(FV) infected mice without CD8+T cells, no expansion of Tregs was observed in
any of the investigated organs. One such study has also reported that the
expansion of Tregs exclusively depended on the presence of virus specific
effector CD4+T cells (1). Viral replication itself or presentation of antigen to virus
specific Tregs have also been attributed to induce Treg expansion (22).
One curious observation we made was the up regulation of HVEM by
Tregs and its viral ligand HSV-1gD was detectable in the draining popliteal lymph
node following HSV infection of the foot pad. Previous reports have shown that
HVEM is up regulated on Tregs and down regulated on T effectors upon
activation. Interestingly our data points towards the maximum Treg numbers and
HVEM up regulation after the peak of effector responses. Additionally highest
levels of HSV-1gD levels were also detected after day 5-post infection (i.e after
peak of effector responses). One plausible explanation of high Treg numbers
after peak of effector responses could be that effector T cells are undergoing a
contraction after peak activity and thus increased Treg representation. Enhanced
up regulation of HVEM could be ligand mediated, as increased availability of
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HSV-1gD was evident at later time points post infection. More direct evidence for
this was obtained by additional in-vitro experiments where stimulation of primed
T cells with UV inactivated HSV kos resulted in further up regulation of HVEM on
Tregs, maximum up regulation again observed when cells were obtained after
peak effector activity. Currently, it is not clear how regulatory T cells are induced
and act to modulate effector cell function following HSV-1 infection, we therefore
undertook these studies to better understand whether the ability of HSV-1gD to
interact with HVEM could alter immune responses. Although HVEM mediates
both positive and negative immune signals (9)`, our observations are more
consistent with the hypothesis that binding of viral ligand gD to HVEM causes T
cells and perhaps only Treg to show activation changes. Evidence suggests that
HSV-1 gD can modulate the activities of the T cell via HVEM during binding,
entry, or egress (7). It has been shown that HVEM is involved in NFkB activation
by HSV-1 gD (11) thus it is conceivable that one consequence of this interaction
might be the NFkB activation in Tregs however; such effects were not formally
investigated.
Further support for the immunomodulatory role of gD HVEM interaction
came from the studies using HVEM knockout mice. Previous reports have
established a role of HVEM in Treg function. One such study reported that HVEM
expression on CD4+CD25+ T regulatory cells was important to mediate the
suppressive functions of Tregs, accordingly HVEM knockout Tregs had
decreased suppressive activity (16). T cells from scurfy mice have been shown to
lack HVEM expression even after activation, suggesting involvement of FoxP3 in
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regulation of HVEM expression. These findings are consistent with our own
observation that Tregs from naïve HVEM knockout mice had reduced
frequencies and FoxP3 expression levels compared to the WT animals. However
more interesting was the observation that following HSV infection the expression
levels of FoxP3 increased on WT Tregs whereas decreased on the HKO Tregs.
Additionally significantly diminished ratios of CD4+FoxP3+Tcells to CD4+FoxP3cells were observed in the HKO mice and again the differences more evident at
day 8p.i. (after the peak of effector responses).This could mean that absence of
gD-HVEM interaction in HKO animals further augments the scenario of
diminished FoxP3 expression on Tregs already existing due to lack of HVEM.
These findings were further supported by our in-vitro experiments that utilized
soluble gD and the effects abolished with anti HVEM antibody. It is still a matter
of debate whether Treg that suppress pathogen specific T-cell responses have to
be pathogen specific themselves. In several infectious diseases, such as
Leishmania (13) or hepatitis C virus (8) pathogen specific Tregs have been found
and in some auto-immune diseases, only antigen specific Tregs were able to
suppress autoreactive T cells, whereas non-specific Tregs were ineffective (21).
However several studies have reported that polyspecific Tregs that are efficiently
recruited to proliferate in the organs with virus induced inflammation can
suppress virus specific T cell responses (22).
Soluble gD has been shown to inhibit T cell proliferation (7). It is
conceivable that gD binding to HVEM might be able to provide a strong negative
signal, the outcome of which is manifested as a defect in T cell proliferation.
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Alternatively our observation might suggest that gD binding to HVEM on Tregs
result in treg activation and expansion which in turn inhibit T cell proliferation.
Thus it is conceivable that same type of receptor ligand interaction might have
different outcome depending on the cell type. In the present study we observed
similar or even attenuated numbers of IFN+ CD4 T cells in the draining PLN of
HKO animals. Because engagement of HVEM on T cells by its natural ligands
may augment (in the case of LIGHT) or attenuate (in the case of BTLA or
CD160) immune response (20) therefore it remains to be studied in more depth
how the balance of these competing interactions condition the kinetics of the
immune response in different cell types.
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Figure 4.1 HSV-1 infection results in the expansion of CD4+FoxP3+
regulatory T cells
FoxP3-GFP knock in mice were infected with 2x105 PFU of HSV kos in a 30 ul
drop in the footpad. The kinetics of FoxP3+ Tregs was measured at indicated
time points in the draining popliteal lymph nodes (PLN) following HSV-I infection
of the footpad. (A) Representative FACS plot showing CD4+FoxP3+ and
CD4+FoxP3- T cells in the pooled (n=4) popliteal lymph nodes of naïve mice. (B)
Histograms depicting the increased frequencies of FoxP3+ Tregs at indicated
time points in the draining PLN following HSV-1 infection. Bar graphs depicting
absolute numbers of CD4 T (C) and CD4+FoxP3+T (D) cells in the draining PLN
of naïve and HSV infected mice at indicated time points post infection. Data are
representative of three independent experiments with 4-5 mice per group in each
experiment. Error bars represent SEM. The level of significance was determined
using one-way ANOVA with Bonferroni post hoc settings.
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Figure 4.2 HVEM expression is up-regulated on regulatory T Cells following
HSV-1 infection and its viral ligand is expressed in PLN following infection
Mice were infected with 2x105 PFU of HSV-1 KOS. At indicated time points
following infection, draining popliteal lymph nodes were collected and flow
cytometry was performed on these samples for expression of HVEM. (A)
Representative FACS plots depicting HVEM expression by FoxP3+ Tregs.
Numbers in the quadrants indicate percent of each subset. (B) HVEM expression
by CD4+FoxP3+T at indicated time points post infection is shown by histograms.
(C) Bar graphs shows the MFI of HVEM expression on FoxP3+T cells. Data are
representative of three independent experiments. Error bars represent SEM. The
level of significance was determined using student’s t test.
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Figure 4.3 Primed cells stimulated with HSV causes HVEM up regulation on
Tregs
FoxP3-GFP knock in mice were infected with 2x105 PFU of HSV KOS in a 30-ul
drop in the footpad. Draining PLN cells were isolated at indicated time points p.i
and stimulated with either UV inactivated HSV kos (MOI = 2) or anti-CD3
(1g/well) anti-CD28 (0.5g/well) for 72 hours. (A) The cells were then analyzed
flow cytometrically for HVEM expression on CD4+FoxP3+ (upper panel) and
CD4+FoxP3- (lower panel) cells. Histograms depicting HVEM expression by unstimulated (shaded area) and UV inactivated HSV kos stimulated (black line). (B)
FACS analysis for HVEM expression on CD4+FoxP3+ (upper panel) and
CD4+FoxP3- (lower panel) cells. Histograms depicting HVEM expression by unstimulated (shaded area) and anti-CD3 anti-CD28 stimulated (black line). (C)
Western blot analysis for detection of HSV-1gD in the draining PLN lysates at
different time points following HSV-1 infection. Draining PLN (2PLN/mice) were
collected and levels of HSV-1gD were detected using rabbit polyclonal anti HSV1gD antibody. Soluble HSV-1gD served as a positive control.
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Figure 4.4 Recombinant HSV-1 gD increases the proportions of FoxP3+ T
cells among CD4+T cells
CD4 T cells were enriched from the splenocytes of naïve mice using miltenyi
biotech kit. Up to around 90% pure CD4 T cells were obtained following
enrichment (A). Enriched naïve CD4 T (5x105) cells were incubated cells with
varying concentration of soluble gD, recombinant human IL-2 and suboptimal
concentrations of anti CD3 (0.5g/ml) for 48 hours. As shown (B) addition of
recombinant gD in the presence of IL-2 increases the proportion of FoxP3+ cells
among the CD4 T cells. (C) Bar graphs depicting the percentages of CD4+
CD25+ FoxP3+ CD4 T cells in the cultures under indicated incubation conditions.
Error bars represent SEM. The level of significance was determined using oneway ANOVA using Bonferroni post hoc settings. In some experiments enriched
CD4 T cells from FoxP3-GFP mice were sorted for FoxP3+ from enriched CD4 T
cell population based on GFP expression. Sorted FoxP3+ cells (2x105 cells) were
then incubated with different concentrations of HSVgD and IL-2 (conc.). CD69
(D) and CD25 (E) expression on sorted FoxP3+T cells following 48hrs postincubation is shown. Data are representative of three independent experiments.
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Figure 4.5 HSV-1gD can help to expand Tregs
CD4 T cells were enriched from the splenocytes of naïve mice using miltenyi
biotech kit and FoxP3+ cells were sorted from enriched CD4 T cell population
based on GFP expression. Representative FACS plots showing presort (A) and
post sort (B) population. (C) CD4+FoxP3+ Treg populations from naive WT mice
were stimulated with anti-CD3 alone, anti-CD3 plus recombinant HSV-1gD, or
anti-CD3 plus anti-CD28 at the indicated concentrations. The proliferation was
determined by [3H]thymidine incorporation. Tregs proliferated significantly at
relatively high concentrations of anti-CD3 with HSV-1gD compared with anti-CD3
alone. (D) CD4+FoxP3+ Treg populations from naive WT mice were stimulated
with anti-CD3 (1 ug/ml), anti-CD3 (1 ug/ml) plus HSV-1gD (1 ug/ml), or anti-CD3
plus HSV-1gD (1 ug/ml) and soluble anti-HVEM Ab (100 ug/ml) as indicated. The
proliferation was determined by [3H] thymidine incorporation. These experiments
were repeated two times. Error bars represent SEM. The level of significance
was determined using student’s t test.
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Figure 4.6 Diminished representations of CD4+FoxP3+ regulatory T cells in
the HVEM knockout mice
CD4+ and CD4+FoxP3+ T cell responses were compared among age and gender
matched HSV-1 infected WT and HKO animals at indicated time points post
infection. Representative FACS plots showing frequencies of CD4+ T cells from
WT and HKO animals in the draining PLN at day 5.5 (A) and day 8 (B) following
HSV-1KOS infection in the footpad. Representative FACS plots showing
CD4+FoxP3+ T cells from WT and HKO animals in the draining PLN at day 5.5
(C) and day 8 (D) following HSV-1kos infection in the footpad. (E) Histograms
depicting FoxP3 expression on CD4T cells in WT (black line) or HKO (shaded
area) mice in draining PLN at day 8 post HSV infection in the foot pad. (F) MFI of
FoxP3 expression in WT and HKO animals at day 8 p.i is shown. HSV-1 infected
mice were pulsed with BrDU 12 hours before sacrifice. At day 8 p.i. (I and J)
draining popliteal lymphoid populations were analyzed by FACS for evidence of
BrDU incorporation. Data are representative of three independent experiments
with 5 mice per group in each experiment. Error bars represent SEM. The level of
significance was determined using student’s t test.
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Figure 4.7 Reduced numbers of CD4+FoxP3+ per CD4+FoxP3-T cells in
HVEM knockout mice
(A) Absolute numbers of CD4+ and CD4+FoxP3+T cells in the draining PLN of WT
and HKO animals at indicated time points as calculated from 4.6 C and D. (B)
Ratios of absolute numbers of CD4+FoxP3+ cells to CD4+T cells at day 5.5 (B)
and day 8 (C) p.i. Ratios of absolute numbers of CD4+FoxP3+ cells to
CD4+FoxP3-T cells at day 5.5 (D) and day 8 (E) p.i. is shown.

166

A

167

Figure 4.8 Diminished frequencies of activated Tregs in HKO animals
(A) Gated CD4+T cells from WT and HKO mice were analyzed at indicated time
points by flow cytometry for co-expression of the Treg surface markers CD25 (A,
B and E), CD103 (C, D and F) and activation marker CD44 (H) with the Treg
associated transcription factor FoxP3. (H) MFI of CD44 expression on WT and
HKO Tregs is shown. CD62L expression on CD4+FoxP3+ cells in WT and HKO
mice at indicated time points is shown. The FACS plots of a representative
mouse are shown. Five animals/group were analyzed, which all gave very similar
results.
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Figure 4.9 Influence of HVEM expressing T regs on outcome of immune
response to HSV.
WT or HKO mice were infected ocularly with 1x104 PFU of HSV RE in a 3-ul drop
in the footpad. Single cell suspension of the infected corneas were prepared from
pooled 6 corneas (n=3) at day 15 p.i. from each group (WT and HKO) of mice.
The cells were labeled for: (A) CD4+ and (B) CD49d (VLA4). The numbers on the
dot plots indicates the percentage of the cells expressing the particular markers
in WT and HKO mice. The experiment was repeated three times and data are
representative of a single experiment.
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Many viruses infect humans and most are controlled satisfactorily by the
immune system with limited damage to host tissues. Some viruses, however, do
cause overt damage to the host, either in isolated cases or as a reaction that
commonly occurs after infection. The outcome is influenced by properties of the
infecting virus, the circumstances of infection and several factors controlled by
the host. In this dissertation, we focus on host factors that influence the outcome
of viral infection, including the induction of anti-inflammatory cells and proteins,
as well as the presence of counter-inflammatory mechanisms. Here we discuss
our current understanding of the circumstances of infection and host-controlled
factors that could explain why an infection can be resolved with minimal impact
or cause substantial tissue damage.
Understanding of the circumstances of infection and host-controlled
factors that could explain why an infection can be resolved with minimal impact
or cause substantial tissue damage could prove to be useful in the future for the
control and perhaps prevention of tissue-damaging virus infection. Accordingly by
inhibiting the factors involved in immunopathology following an acute viral
infection or manipulating the immunomodulatory factors such as some cytokines,
groups of molecules derived from omega-3 polyunsaturated fatty acids, as well
as some of the carbohydrate binding proteins of the galectin family and co
stimulatory

molecules

like

HVEM

could

be

beneficial

immunopathology and to enhance immune responses to vaccines.
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